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A B S T R A C T
Background
High-dose or dose-intensive cytotoxic chemotherapy often causes myelosuppression and severe neutropenia among cancer patients.
Severe neutropenia accompanied by fever, named febrile neutropenia (FN), is the most serious manifestation of neutropenia usually
requiring hospitalization and intravenous antibiotics. FN and neutropenia can lead to chemotherapy treatment delays or dose reductions,
which potentially compromises the effectiveness of cancer treatment and prospects for a cure. Granulocyte-macrophage (GM) and
granulocyte colony-stimulating factors (G-CSFs) are administered during chemotherapy in order to prevent or reduce the incidence or
the duration of FN and neutropenia.
Objectives
To assess the effect of prophylactic colony-stimulating factors (CSFs) in reducing the incidence and duration of FN, and all-cause and
infection-related mortality during chemotherapy in patients with breast cancer.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, HEALTHSTAR, International
Health Technology Assessment, SOMED, AMED and BIOSIS up to 8 August 2011. We also searched three Chinese databases (VIP,
CNKI, CBM), the metaRegister of Controlled Trials, ClinicalTrials.gov, the World Health Organization’s International Clinical Trials
Registry Platform (WHO ICTRP) and OpenGrey.eu up to August 2011.
Selection criteria
Randomized controlled trials (RCTs) comparing CSFs (any dose) with placebo or no treatment in patients with breast cancer at any
stage, at risk of developing FN while undergoing any type of chemotherapy.
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Data collection and analysis
We used pooled risk ratios (RR) with 95% confidence intervals (CIs) for binary outcomes. At least two review authors independently
extracted data and assessed the risk of bias of the included studies. Trial authors were contacted for further details when information
was unclear.
Main results
We included eight RCTs involving 2156 participants with different stages of breast cancer and chemotherapy regimens. The trials were
carried out between 1995 and 2008 and judged as being at least at moderate risk of bias. The strength of the evidence was weak for
the majority of outcomes, which was mostly because of the small numbers of evaluable patients, varying definitions, as well as unclear
measurements of the trials’ outcomes and uncertain influences of supportive treatments on them. In most trials, the chemotherapy
regimens had a risk of FN that was below the threshold at which current guidelines recommend routine primary prophylaxis with CSFs.
Using CSFs significantly reduced the proportion of patients with FN (RR 0.27; 95% CI 0.11 to 0.70; number needed to treat for
an additional beneficial outcome (NNTB) 12) but there was substantial heterogeneity which can be explained by possible differential
effects of G-CSFs and GM-CSFs and different definitions of FN. A significant reduction in early mortality was observed in CSF-treated
patients compared to placebo or no treatment (RR 0.32; 95% CI 0.13 to 0.77; NNTB 79). This finding was based on 23 fatal events
in 2143 patients; wherein 19 of these 23 events occurred in one study and 17 events were attributed to progression of the disease by the
study authors. For infection-related mortality, there were no significant differences between CSF and control groups (RR 0.14; 95% CI
0.02 to 1.29). In CSF-treated patients, the risk for hospitalization was significantly reduced (RR 0.14; 95% CI 0.06 to 0.30; NNTB
13), as well as the use of intravenous antibiotics (RR 0.35; 95% CI 0.22 to 0.55; NNTB 18). The risks of severe neutropenia, infection
or not maintaining the scheduled dose of chemotherapy did not differ between CSF-treated and control groups. CSFs frequently led
to bone pain (RR 5.88; 95% CI 2.54 to 13.60; number needed to treat for an additional harmful outcome (NNTH) 3) and injection-
site reactions (RR 3.59; 95% CI 2.33 to 5.53; NNTH 3).
Authors’ conclusions
In patients with breast cancer receiving chemotherapy, CSFs have shown evidence of bene t in the prevention of FN. There is evidence,
though less reliable, of a decrease of all-cause mortality during chemotherapy and a reduced need for hospital care. No reliable evidence
was found for a reduction of infection-related mortality, a higher dose intensity of chemotherapy with CSFs or diminished rates of
severe neutropenia and infections. The majority of adverse events reported from CSF use were bone pain and injection-site reactions
but no conclusions could be drawn regarding late-term side effects.
P L A I N L A N G U A G E S U M M A R Y
Prophylactic colony-stimulating factors to prevent infectious complications in patients with breast cancer undergoing chemo-
therapy
Patients with breast cancer receiving chemotherapy have an increased risk of infection mediated through a low number of protective
white blood cells (neutropenia). Neutropenia is a common toxicity of many chemotherapy agents and is caused by the suppression of
the bone marrow. The first sign of infection is usually a fever, which indicates a potentially life-threatening condition if it occurs during
severe neutropenia (febrile neutropenia (FN)). FN requires hospital care including the administration of intravenous antibiotics and
possible delays in the continuation of chemotherapy. Colony-stimulating factors (CSFs) are drugs administered during chemotherapy
in order to prevent or reduce the incidence or duration of FN and neutropenia. This review included eight trials in which 2156 patients
with breast cancer had randomly received CSFs or placebo or no treatment during chemotherapy. These trials were carried out between
1995 and 2008. Prophylactic treatment with CSFs significantly reduced the risk of developing FN by 73%. The estimated number of
patients needed to be treated with CSFs in order to prevent one event of FN was 12. Although a significant decrease in mortality of all
causes during chemotherapy and CSF therapy was noted, there was no reduction in infection-related mortality. There was no significant
effect observed that planned chemotherapy schedules could be better maintained if CSFs were administered or that the number of
patients with neutropenia decreased with CSFs. Notably, CSFs significantly reduced the need for hospital care yet frequently caused
short-term adverse effects like bone pain and injection-site reactions. There were several limitations in this analysis: only a few trials could
be included, the number of patients was low inmany of these trials, and disease stages and chemotherapy treatments varied considerably.
Moreover, the trial authors defined their outcomes differently, making comparisons across studies difficult. Information on the primary
and secondary outcomes could not be obtained from all trials and the overall reporting quality was low. Many studies were dated and
hence the administration of CSFs did not comply with current recommendations. Overall, CSFs have shownmoderate evidence of bene
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t in the prevention of FN in patients with breast cancer receiving chemotherapy. The evidence that the administration of CSFs could
reduce early mortality of all causes was weak and substantiates the need of further studies. There was no reduction in risk of infection-
related mortality with CSF treatment.
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B A C K G R O U N D
Description of the condition
Chemotherapy still plays a major role in the treatment of patients
with breast cancer. It is widely used as an adjuvant treatment in
patients following primary removal of tumors to attain cure and to
prevent recurrence, and as a palliative treatment in patients with
metastatic disease. Palliative chemotherapy aims to induce tumor
remission, to prolong survival, to control symptoms, and to main-
tain or improve quality of life. As with any other treatment, the
potential benefits of either adjuvant or palliative chemotherapy
for breast cancer must be balanced against the potential risks of
treatment-related morbidity and mortality. Chemotherapy causes
a wide range of adverse effects and can result in symptoms that
are debilitating and that seriously impact on patients’ quality of
life. Nausea and vomiting, loss of hair and changes in blood cell
counts constitute the most frequent, acute adverse effects. The
changes in blood cell counts comprise a decrease in the number of
red cells (anemia), platelets (thrombocytopenia) and white blood
cells (leukopenia). While leukopenia means a decrease of all types
of white blood cells, the term neutropenia describes a diminished
number of neutrophil granulocytes. Neutrophils act as the first
line of cellular defense against infectious agents. An episode of
fever during the period of neutropenia is called febrile neutrope-
nia (FN). FN is defined as a rise in axillary temperature to > 38.5
°C for a duration of more than one hour while having an abso-
lute neutrophil count (ANC) of less than 0.5 × 109/L (Crawford
2010). The risk of FN is directly related to the severity and dura-
tion of neutropenia (Bodey 1966). Although FN does not neces-
sarily imply a documentable infection, it is most likely an indicator
of some infectious condition. Once it occurs there is little chance
to clarify the reasons (bacteria, virus, fungi, tumor-related) within
a short period of time. Therefore FN is always managed like a
severe infection. Infectious complications during neutropenia are
potentially life threatening and mortality rates associated with FN
range from 2% to 21% (Smith 2006). Episodes of FN not only in-
crease the costs of treatment through the required hospitalization
(Crawford 2004) but could also lead to delays of chemotherapy or
necessitate dose-reduction of chemotherapy. However, this creates
a difficult clinical situation since the timing and dosage of cyto-
toxic substances are crucial elements that determine the success of
a chemotherapeutic treatment (Samson 1984). Hence, reducing
dose intensity or dose density of chemotherapy is clinically unde-
sirable as it might jeopardize its effectiveness.
Description of the intervention
During the 1960s, the concept of the formation of mature blood
cells from hematopoietic stem cells was established on an experi-
mental basis usingmainlymurine assays. Immature cells frombone
marrow, when given to culture plates, give rise to different colonies
or colony-forming units (CFU), as bacteria dowhen plated on agar
(Bradley 1966; Pike 1970). For the myeloid lineage, these aggre-
gates were termed colony-forming unit granulocyte macrophage
(CFU-GM) and colony-forming unit granulocyte (CFU-G). Two
distinct cytokines called colony-stimulating factors (CSFs) were
found to induce each type of the observed colonies: GM-CSF and
G-CSF. Both CSFs became available for clinical use during the
late 1980s and different types of GM-CSF and G-CSF are avail-
able on the market. Filgrastim and lenograstim are the most com-
monly used G-CSFs and sargramostim and molgramostim are the
most commonly used GM-CSFs. Since 2002, a long-acting form
of filgrastim linked to polyethylene glycol, pegfilgrastim, and sev-
eral officially approved subsequent versions of filgrastim, so-called
biosimilars, have been available (Jelkmann 2010; Petros 2003).
G-CSFs and, to a much lesser extent, GM-CSFs are being used
during chemotherapy in patients with breast cancer for two main
purposes: (1) as concomitant treatment to antibiotics in febrile
neutropenic patients or (2) as prophylactic treatment either start-
ing with the rst cycle of chemotherapy if neutropenia is likely to
occur, or in cases where severe neutropenia is already documented
(primary prophylaxis), or in patients who have already experienced
infectious complications during neutropenia in earlier cycles of
chemotherapy (secondary prophylaxis).
How the intervention might work
GM-CSFs expand the compartment of granulocyte andmonocyte
precursor cells in the bone marrow, thereby increasing the number
of mature granulocytes and monocytes in the blood stream. The
action of G-CSFs is not restricted but concentrated to the granulo-
cyte lineage, leading not only to a dramatic increase of neutrophils
in the peripheral blood (Lyman 2010), but also a reduction in
the maturation time from stem cell to the neutrophil granulocyte
(Lyman 2010). In addition to their growth promoting actions,
CSFs exert effects on phagocytosis, motility, bactericidal activity,
and surface molecule expression of neutrophils and monocytes
(Carulli 1997; Fazzi 2007). Hence, the ef cacy of CSFs is believed
to not only function via a shortening of the neutropenic episode
but also by increasing the anti-infectious capacity ofmyeloid blood
cells.
Why it is important to do this review
An effective prophylaxis of FN during chemotherapy would ide-
ally decrease infection-related morbidity and mortality without
the need for dose reductions or delays of chemotherapy. There is
evidence that CSFs might be effective agents to prevent FN in
cancer patients receiving chemotherapy, but the debate on the best
prevention strategy remains controversial (Herbst 2009; Kuderer
2006).Current guidelines recommend the prophylactic use ofCSF
in cancer chemotherapies with an estimated risk of FN of about
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20% and in patients who have already experienced a febrile neu-
tropenic episode (Aapro 2011; Crawford 2007; Crawford 2010;
Smith 2006). However, observational data suggest that the utiliza-
tion of CSFs does not comply with current guidelines (Ramsey
2010). Considering the prevalence of breast cancer, the high costs
of infectious complications after chemotherapy and of CSF them-
selves, and the fact that there is no systematically synthesized ev-
idence from randomized controlled trials (RCTs) concerning the
efficacy and safety of G-CSFs and GM-CSFs in breast cancer, a
systematic review and meta-analysis on this topic are justified.
O B J E C T I V E S
To identify, assess, meta-analyze and summarize the evidence con-
cerning the efficacy and safety of primary prophylactic CSFs (G-
CSFs or GM-CSFs) compared to placebo or no treatment for the
prevention of FN, early mortality and infection-related mortality
in patients with breast cancer undergoing chemotherapy.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs that compared the use of any kind of either G-CSFs or GM-
CSFs versus no treatment or placebo for the prevention of neu-
tropenia and neutropenia-related complications in patients with
breast cancer undergoing chemotherapy.
Types of participants
Patients with breast cancer at any stage of disease undergoing treat-
ment with any type and dosage of chemotherapy who were at risk
of experiencing FN or neutropenia.
Types of interventions
The intervention group received any kind of eitherG-CSF orGM-
CSF at any administered dosage as primary prophylaxis during
each cycle of a standard non-myeloablative chemotherapy prior to
the onset of neutropenia in the treatment of breast cancer.
The control group had to receive the identical chemotherapy reg-
imen as the intervention group and a placebo or no treatment was
given instead of G-CSF or GM-CSF.
If studies assessed primary CSF prophylaxis in the intervention
arms and allowed secondary CSF prophylaxis in control arms in
subsequent cycles, studieswere includedbutwe used only outcome
data of cycle one (except for hard outcomes: mortality data) in our
meta-analysis.
We excluded trials investigating the sequential administration of
G-CSF or GM-CSF or their administration as secondary prophy-
laxis. We also excluded trials in which CSFs were administered
before chemotherapy in order to induce a state of hematopoietic
stem-cell arrest (i.e. priming).
Types of outcome measures
Primary outcomes
• Proportion of patients with FN.
• Duration of FN (definition of FN is described for each
study).
• Early mortality (mortality during the study).
• Infection-related mortality (during the study).
Secondary outcomes
• Proportion of patients with neutropenia.
• Duration of neutropenia (definition of neutropenia is
described for each study).
• Proportion of patients being hospitalized or treated, or
both, with antibiotics because of FN.
• Duration of hospitalization and antibiotic treatment.
• Administration of chemotherapy (e.g. number of dose
delays or dose reductions, relative dose intensity).
• Incidence of CSF-related adverse effects (e.g. bone pain and
injection-site reaction).
Search methods for identification of studies
See: Breast Cancer Group methods used in reviews.
Electronic searches
Deutsches Institut für Medizinische Dokumentation und
Information (DIMDI)
We searched the following databases in DIMDI (8 August 2011):
Deutsche Ärzteblatt, Global Health, BIOSIS, AMED, CCMED,
the Cochrane Central Register of Controlled Trials (CEN-
TRAL), Database of Reviews of Abstracts of Effects, Cochrane
Database of Systematic Reviews, EMBASE, EMBASE Alert,
Hogrefe Verlagsdatenbank und Volltexte, SciSearch, Krause &
Pachernegg Verlagsdatenbank, Karger Verlagsdatenbank, MED-
LINE, MEDIKAT, NHS Economic Evaluation database, Thieme
Verlagsdatenbank and Thieme Verlagsdatenbank PrePrint. The
corresponding search strategy can be seen in Appendix 1. We
placed no language restrictions.
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Gray literature
For ongoing trials, we searched the ClinicalTrials.gov (
clinicaltrials.gov) and the World Health Organization’s Interna-
tional Clinical Trials Registry Platform (WHO ICTRP) for tech-
nical or research reports, doctoral dissertations and conference pa-
pers. We accessed OpenGrey.eu (August 2011). The search strate-
gies used on these databases are in Appendix 2.
Chinese databases
One review author (JPL) conducted searches on three Chinese
medical databases (VIP, CNKI and CBM; accessed September
2011). Translations of the trials of interest published in Chinese
were conducted by the same review author. The corresponding
search strategy can be seen in Appendix 3.
Searching other resources
References from published studies
We screened the reference lists of all located studies for eligible trials
by titles first and thereafter screened abstracts of studies of possible
interest. Where possible, we obtained a copy of the full article
for each reference reporting a potentially eligible trial. Where this
was not possible, we attempted to contact the authors to provide
additional information. We did not impose language restrictions.
Studies that could be excluded after reading the full article were
labeled as excluded trials and reasons for exclusion were stated in
the Characteristics of excluded studies section.
Unpublished literature
We tried to identify unpublished or ongoing trials through corre-
spondence with experts in the field. We did not impose language
restrictions.
Data collection and analysis
Selection of studies
All titles, study information and abstracts retrieved from the
electronic searches were downloaded to a reference management
database. After the removal of duplicates, screening of the title,
abstract and full-text was performed independently by at least two
review authors (PR, SM, MH, JL). Assessment for eligibility of
the full texts of all potentially relevant references was carried out
using an eligibility form that contained the following questions:
• Was the study described as randomized?
• Were the participants being treated with chemotherapy for
breast cancer?
• Did patients in the study arms of interest receive the same
chemotherapy?
• Were patients of at least one arm given CSFs (the factors
include G-CSF or GM-CSF)?
• Did patients of at least one arm receive placebo or no
treatment instead of CSF?
• Did the study report at least one of the outcome measures
defined in the protocol (see “Types of outcome measures”)?
All studies that fulfilled all of the aforementioned criteria were
included. In case of disagreement between two review authors, a
third review author was consulted.
Data extraction and management
Data extraction
Two review authors (PR, SM) independently extracted data on the
characteristics of patients and interventions, study quality compo-
nents and outcomes onto a data extraction form especially devel-
oped for the review. We resolved differences by discussion or by
appeal to a third review author (MH), if necessary. We accounted
for both clinical and methodological differences of the individual
trials. Data for meta-analysis were either extracted from the orig-
inal publications of the included trials or from other published
versions of the trials or were used from additional information that
trial authors provided.
Assessment of risk of bias in included studies
We applied the guidelines delineated in the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011) for the judg-
ment of risk of bias. They were applied according to the following
six domains:
• sequence generation;
• allocation concealment;
• blinding of participants, personnel and outcome assessors;
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias.
When the retrieved information was not available, we contacted
the authors of the trial publications to provide the information.
Furthermore, we assessed the quality of evidence using theGrading
of Recommendations Assessment, Development and Evaluation
(GRADE) approach (Higgins 2011).
Measures of treatment effect
The decision on whether or not to combine the results of the
included studies in a meta-analysis depended on the similarity of
trial characteristics and the number of trials reporting on each
outcome. For dichotomous variables, we calculated individual and
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pooled statistics as risk ratios (RR) with 95% confidence intervals
(CI). In the case where we obtained significant results in our meta-
analysis, we calculated the number needed to treat for an additional
beneficial outcome (NNTB) and absolute risk reduction (ARR)
using a 2 × 2 table (www.ebem.org/nntcalculator.html).
Assessment of heterogeneity
We assessed the heterogeneity of treatment effect between trials by
visual inspection of the forest plots, and by using the standard Chi
2 test with a significance level of 0.1. We also examined hetero-
geneity using the I2 statistic and used thresholds for the interpre-
tation according to the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). When we detected heterogeneity,
we sought reasons for it by examining clinical and methodological
characteristics of the individual study and considered the appro-
priateness of reporting a pooled estimate. Heterogeneity was cat-
egorized into four groups depending on the I2 (Higgins 2011):
• 0% to 30%: low;
• 30% to 50%: moderate;
• 50% to 75%: substantial; and
• 75% to 100%: considerable heterogeneity.
Data synthesis
The study data were pooled using a fixed-effectmodel. A priori, we
assumed only one true estimate and low levels of heterogeneity for
all outcomes. In cases where we detected substantial or consider-
able heterogeneity that could not be declared by specific instances,
we used a random-effects model for the respective outcome.
Subgroup analysis and investigation of heterogeneity
We performed subgroup analyses only if one of the outcome pa-
rameters demonstrated statistically significant differences between
treatment groups and we regarded all subgroup analyses as hy-
pothesis-generating. Where possible, we explored the impact of
the type of CSF and the duration of CSF administration (either
only in cycle one or across all delivered cycles) on outcomes in a
subgroup analysis.
Sensitivity analysis
In general we abandoned sensitivity or post-hoc analysis but where
necessary we performed sensitivity analysis owing to moderate to
considerable heterogeneity among studies in the meta-analysis.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The search strategy identified a total of 1023 citations from which
we removed 232 duplicates. In total, screening of the titles and
abstracts identified 46 potentially eligible citations. The full-text
screening of the 46 publications identified 16 articles that per-
tained to eight eligible RCTs (Figure 1).
The agreement between review authors for study eligibility was
excellent (kappa > 0.9). Reasons for the exclusion of studies are
described in the Characteristics of excluded studies table.
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Figure 1. Study flow diagram.
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Included studies
Eight trials were included in the review (Chevallier 1995; Del
Giglio 2008; Hansen 1995; Jones 1996; Muhonen 1996; Papaldo
2003; Romieu 2007; Vogel 2005) and study details are shown in
the Characteristics of included studies table. Two trials were con-
ducted in France (Chevallier 1995; Romieu 2007) and one of each
in the US (Jones 1996), Denmark (Hansen 1995), Italy (Papaldo
2003), Brazil (Del Giglio 2008) and Finland (Muhonen 1996).
Six trials were multicenter studies (Chevallier 1995; Del Giglio
2008;Muhonen 1996; Papaldo 2003; Romieu 2007; Vogel 2005)
and Vogel 2005 and Del Giglio 2008 were multinational stud-
ies. In addition to the original publication (Papaldo 2003), four
papers reported further on this study (Di Cosimo 2005; Papaldo
2004; Papaldo 2005; Papaldo 2006). Data concerning economic
outcomes and a 10-year follow-up of Chevallier 1995 was pub-
lished by Mapelli 1994 and Veyret 2006. Brugger 2009 presented
further data of Romieu 2007. Sharma 2004 is a summary of the
main findings of Vogel 2005. All study authors were contacted
for additional information; however, only two authors kindly pro-
vided additional data (Hansen 1995; Papaldo 2003).
Participants
A total of 2156 adult patients (2148 women; eight men) were
included in the eight studies (range: 20 to 928;mean: 270;median:
131). The age of the patients ranged from 18 to 78 years and the
mean age was approximately 50 years. Romieu 2007 only included
patients older than 65 years.
Treatment situations
Three studies treated patients with localized stages and adju-
vant chemotherapies after surgery (Jones 1996; Papaldo 2003;
Romieu 2007), one with inflammatory breast cancers and neoad-
juvant chemotherapy before surgery (Chevallier 1995) and four
with metastatic diseases and palliative chemotherapies (Del Giglio
2008; Hansen 1995, Muhonen 1996, Vogel 2005; for details of
used chemotherapy regimens see Table 1).
Intervention and control treatments
Six trials used G-CSF: one trial compared lenograstim with
placebo (Chevallier 1995), two trials compared pegfilgrastim with
placebo (Romieu 2007; Vogel 2005), two trials used filgrastim
compared with no treatment (Muhonen 1996; Papaldo 2003) and
one trial used a biosimilar filgrastim (non-glycosylated r-metHuG-
CSF) compared with filgrastim and with no treatment (Del Giglio
2008).
Two trials used GM-CSF: one trial compared sargramostim with
placebo (Jones 1996) and one trial compared GM-CSF with no
treatment (Hansen 1995). For details of applied type of CSF refer
to Table 2.
Study designs
In all eight studies, patients were treated in parallel designs. Six
studies were made up of two study groups, one study was made up
of three groups, one study was made up of four groups. All studies
included at least four chemotherapy cycles up to a maximum of six
cycles. Three studies used true double-blind designs (Chevallier
1995; Jones 1996; Vogel 2005) and in four studies, patients of the
control groups were treated with placebo (Chevallier 1995; Del
Giglio 2008; Jones 1996; Vogel 2005).
In Jones 1996, Romieu 2007 and Vogel 2005, all patients devel-
oping an event of FN at any time during the study were treated
with CSFs in all subsequent cycles. Del Giglio 2008 dismantled
the control group after cycle one and all patients of this group
received the study drug in subsequent cycles. Romieu 2007 com-
pared primary and secondary prophylaxis of pegfilgrastim, and
patients who developed FN in the control group in cycle one re-
ceived pegfilgrastim in all following cycles.
Outcomes
Two trials (Jones 1996; Vogel 2005) described the number of pa-
tients with FN as the primary outcome. The six remaining trials
reported different primary outcomes: duration of grade IV neu-
tropenia (Chevallier 1995; Del Giglio 2008; Jones 1996), number
of neutropenic events (Romieu 2007), disease-free survival (DFS;
Papaldo 2003) and duration of severe neutropenia (Hansen 1995).
Trial authors’ definitions and measurements of outcomes varied
considerably (see Table 3).
Febrile neutropenia
All but one study (Muhonen 1996) provided data concerning
FN. Six studies reported on the rates of patients developing FN
(Chevallier 1995; Del Giglio 2008; Jones 1996; Papaldo 2003;
Romieu 2007; Vogel 2005), one study reported on the number
of febrile episodes (Papaldo 2003) and one study (Hansen 1995)
reported the duration of FN events in days.
Early mortality and infection-related mortality
Four studies reported data on all-causemortality (Del Giglio 2008;
Jones 1996; Romieu 2007; Vogel 2005) and five studies reported
on infection-related mortality during the study (Chevallier 1995;
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DelGiglio 2008; Jones 1996; Romieu 2007; Vogel 2005). In those
studies where the authors did not report on mortality, we assumed
that no deaths had occurred.
Severe neutropenia
Four trials reported on the rates of patients with severe (WHO
grade IV) neutropenia (Jones 1996; Muhonen 1996; Papaldo
2003; Romieu 2007).
Infections
Three studies reported on the incidence of infections (Chevallier
1995; Muhonen 1996; Romieu 2007). Chevallier 1995 distin-
guished between fever of unknown origin and clinically or micro-
biologically documented infections. Romieu 2007 and Muhonen
1996 stated only the number of patients with infections.
Hospitalization
Two trials reported on the rate of patients being hospitalized be-
cause of FN (Jones 1996; Vogel 2005), while three trials reported
on the duration of hospitalization for any reason (Chevallier 1995;
Hansen 1995; Muhonen 1996).
Use of antibiotics
Four trials reported on the rates of patients treated with intra-
venous (i.v.) antibiotics because of FN (Hansen 1995; Jones 1996;
Papaldo 2003; Vogel 2005) and two trials on the duration of treat-
ment with i.v. antibiotics (Chevallier 1995; Hansen 1995).
Administration of chemotherapy
Four studies reported the percentage or the number of patients
who received the planned chemotherapy doses at scheduled times
and doses (Chevallier 1995; Papaldo 2003; Romieu 2007; Vogel
2005). Three studies (Chevallier 1995; Hansen 1995; Papaldo
2003) reported the number of patients who received all planned
cycles. Two further studies reported dose reductions of single che-
motherapy agents (Muhonen 1996; Jones 1996); however, the re-
porting quality was so low that the data could not be used.
Adverse events
All studies reported short-term adverse events related to CSF use.
The most common were injection-site reactions and bone pain.
We extracted data concerning injection-site reactions from two
studies (Chevallier 1995; Jones 1996) and bone pain from three
studies (Chevallier 1995; Muhonen 1996; Papaldo 2003), which
reported rates for both study arms. Late-term adverse events were
not reported in any of the included trials.
Conflicts of interests
Three trials explicitly declared possible conflicts of interest (Del
Giglio 2008; Romieu 2007; Vogel 2005) and five trials acknowl-
edged assistance from the pharmaceutical industry and supply of
study medication (Chevallier 1995; Del Giglio 2008; Muhonen
1996; Romieu 2007; Vogel 2005). In the Vogel 2005 trial, six out
of the eight authors were affiliated with the manufacturer of the
interventional drug. No details about the source of the study med-
ication were provided in Hansen 1995, Jones 1996 and Papaldo
2003.
Excluded studies
Trials that were first considered to be of possible relevance but
were subsequently excluded can be viewed at the Characteristics
of excluded studies table. The main reasons for excluding trials
were different chemotherapy regimens between study groups and
missing control groups. No ongoing studies or studies awaiting
classification were suitable for inclusion at the time point when
we conducted the review.
Risk of bias in included studies
The quality of the included studies and their risk of bias were as-
sessed separately for the different outcomes of primary interest (FN
and early/infection-relatedmortality). The studies are grouped be-
low by the grades of risk of bias.
The included studies were judged as having the following risk of
bias concerning FN:
• low: Chevallier 1995;Jones 1996;
• moderate: Del Giglio 2008;Vogel 2005;
• moderate to high: Papaldo 2003; Romieu 2007;
• high: Hansen 1995.
Muhonen 1996 did not report on this outcome. The funnel plot
of the six studies reporting the numbers of patients developing at
least one event of FN suggested potential publication bias owing
to missing studies reporting results to the right-hand side of the
drawn effect-size. Assessing funnel plots of outcomes other than
FN was impossible owing to the small number of studies.
The included studies were further judged as having the following
risk of bias concerning early mortality and infection-related mor-
tality:
• low: Chevallier 1995;Jones 1996;
• low to moderate: Del Giglio 2008;Romieu 2007;
• moderate: Hansen 1995;Muhonen 1996; Papaldo 2003;
Vogel 2005.
Overall, the reasons for higher grades of risk of bias were because of
inadequate reporting of the methods used for random allocation,
unblinded study designs, unbalanced risk factors for the outcome
of interest, inadequate definitions and measurements of outcomes
(Table 3), different supportive treatment between groups and small
sample sizes. To allow for comparisons, we assessed the quality of
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each study using the Jadad scale, which resulted in an average score
of 2.3 of a maximum of 5 (range: 1 to 4) and the Delphi scale with
an average score of 4.6 of a maximum of 7 (range: 4 to 7).
For the risk of bias of the included studies in detail refer to the
Characteristics of included studies, Figure 2 and Figure 3.
Figure 2. ’Risk of bias’ graph: review authors’ judgments about each ’Risk of bias’ item presented as
percentages across all included studies.
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Figure 3. ’Risk of bias’ summary: review authors’ judgments about each ’Risk of bias’ item for each included
study.
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Effects of interventions
See: Summary of findings for the main comparison Prevention
of chemotherapy-induced FN in breast cancer patients - primary
outcomes; Summary of findings 2 Prevention of chemotherapy-
induced FN in breast cancer patients - secondary outcomes
For the analyses, we used first-cycle data from Jones 1996, Romieu
2007 and Vogel 2005. In these three studies, CSFs were applied as
secondary prophylaxis in case of developing a febrile neutropenic
event in patients of the control groups from cycle two and did not
met the inclusion criteria in these cycles. Data of cycles two to
four of Del Giglio 2008 could not be used for analysis because the
control group was dissolved after the first cycle in this study. We
used cumulated data across all cycles of the four remaining trials
(Chevallier 1995; Hansen 1995; Muhonen 1996; Papaldo 2003).
Febrile neutropenia
Number of patients
In six studies, a total of 79 of 1137 patients in the intervention
groups and 141 of 936 patients in the control groups developed
at least one episode of FN (Chevallier 1995; Del Giglio 2008;
Jones 1996; Papaldo 2003; Romieu 2007; Vogel 2005; Table 4).
The pooled risk of FN was significantly reduced in CSF-treated
patients (RR 0.27; 95% CI 0.11 to 0.70; Analysis 1.1; Figure 4).
The percentage of the variability in the effect estimates owing to
heterogeneity rather than by chance was substantial (I2 = 89%;
NNTB 12; ARR 0.08). When we analyzed the data without
Chevallier 1995, who defined FN in a broader way, heterogeneity
was reduced (I2 = 50%). There was no heterogeneity (I2 = 0%)
when we excluded Vogel 2005 and Romieu 2007 (two studies that
used pegfilgrastim). The treatment benefit of the filgrastim-treated
patients in the three remaining studies remained significant (RR
0.32; 95% CI 0.21 to 0.48).
Figure 4. Forest plot of comparison: 1 Primary outcomes, outcome: 1.1 number of patients with at least
one event of FN during the study period.
Subgroup analyses
First-cycle data and cumulated data across all chemotherapy
cycles
Two studies reported on cumulated FN rates across all cycles.
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Thirty-nine of 298 patients in the intervention groups and 58
of 300 patients in the control groups had at least one episode of
FN (Chevallier 1995; Papaldo 2003). The pooled RR was 0.44
and not significant (95% CI 0.09 to 2.24) with substantial het-
erogeneity (I2 = 86%; Analysis 1.2). Four studies reported on FN
rates during the first cycle of chemotherapy. Forty of 839 patients
in the intervention groups and 83 of 636 patients in the con-
trol groups developed FN (Del Giglio 2008; Jones 1996; Romieu
2007; Vogel 2005). The risk of FN was significantly reduced in
CSF-treated patients (RR 0.20; 95% CI 0.08 to 0.52) with sub-
stantial heterogeneity (I2 = 61%; Analysis 1.3). Heterogeneity dis-
appeared when two pegfilgrastim studies were excluded (Romieu
2007; Vogel 2005; I2 = 0%), while the RR remained significant
(RR 0.34; 95% CI 0.22 to 0.53). Both pegfilgrastim studies also
remained free from heterogeneity (I2 = 0%) and showed signifi-
cant treatment benefits (RR 0.10; 95% CI 0.04 to 0.24).
G-CSF and GM-CSF
In the five G-CSF studies, 78 of 1067 patients in the intervention
groups and137of 864patients in the control groups developedFN
(RR0.23; 95%CI 0.11 to 0.46; Chevallier 1995;DelGiglio 2008;
Papaldo 2003; Romieu 2007; Vogel 2005) and heterogeneity was
substantial (I2 = 62%). The GM-CSF study reported one of 70
patients in the interventional groups and four of 72 patients in
the control groups with FN and this did not result in a significant
treatment benefit for GM-CSF-treated patients (RR 0.25; 95%
CI 0.03 to 2.26; Jones 1996).
Duration
Only one study (Hansen 1995) reported on the duration of febrile
neutropenic events and reported a non-significant difference of
one day between the intervention group (median: four days) and
the control group (median: five days) across all cycles.
Early mortality
In all eight studies, six of 1181 patients in the intervention groups
and 17 of 962 patients in the control groups died during the
study (Chevallier 1995; Del Giglio 2008; Hansen 1995; Jones
1996;Muhonen 1996; Papaldo 2003; Romieu 2007; Vogel 2005).
Causes of death are listed in Table 5. The early mortality risk
was significantly lower in CSF-treated patients (RR 0.32; 95%
CI 0.13 to 0.77) without heterogeneity among the trials (I2 =
0%; NNTB 79; ARR 0.01; Analysis 1.4; Figure 5). The RR of
early mortality was mainly affected by the large study of Vogel
2005, which reported five versus 14 deaths in the control and
intervention group, respectively. The significance of the difference
disappeared when Vogel 2005 was excluded from analysis (RR
0.19; 95% CI 0.03 to 1.24).
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Figure 5. Forest plot of comparison: 1 Primary outcomes, outcome: 1.4 Early mortality during the study
period.
Infection-related mortality
In all eight studies, none of the 1181 patients in the intervention
groups and three of 962 patients in the control groups died of
infections. Two of the three deaths occurred in Vogel 2005 and
one in Del Giglio 2008. Causes of deaths are listed in Table 6. The
differences in the risk of dying from infection were not significant
(RR 0.14; 95% CI 0.02 to 1.29; Analysis 1.5; Figure 6). The
results were homogeneous (I2 = 0%; Analysis 1.5).
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Figure 6. Forest plot of comparison: 1 Primary outcomes, outcome: 1.5 Infection-related mortality.
Neutropenia
Number of patients
In four studies, a total of 83 of 353 patients in the intervention
groups and 191 of 359 patients in the control groups developed
at least one episode of severe (WHO grade IV) neutropenia (N4)
(Jones 1996; Muhonen 1996; Papaldo 2003; Romieu 2007 Table
4). The risk of N4 was not significantly reduced in CSF-treated
patients (RR 0.44; 95% CI 0.17 to 1.18) with considerable het-
erogeneity among the studies (I2 = 96%; Analysis 2.1). Hetero-
geneity could not be further reduced.
Subgroup analyses
First-cycle data and cumulated data across all chemotherapy
cycles
We used data from Muhonen 1996 and Papaldo 2003 who re-
ported rates of patientswith neutropenia across all cycles of chemo-
therapy. Seventeen of the 253 patients in the intervention group
and 113 of 258 patients in the control group developed at least
one neutropenic event that was significant (RR 0.19; 95%CI 0.08
to 0.45; Analysis 2.2). In two studies (Jones 1996; Romieu 2007)
that reported the rates of patients who developed at least one neu-
tropenic event during cycle one, 66 of 100 patients in the inter-
vention group and 78 of 101 patients in the control group de-
veloped at least one neutropenic event. The meta-analysis showed
no significant benefits for CSF-treated patients (RR 0.89; 95%
CI 0.66 to 0.21; Analysis 2.3). Both subgroup analyses were of
substantial heterogeneity (I2 = 0.64 and I2 = 0.63, respectively).
G-CSF and GM-CSF
In the three studies (Muhonen 1996; Papaldo 2003; Romieu
2007) applyingG-CSFs, 40 out of 283 patients in the intervention
group and 134 of 287 patients in the control group developed at
least one neutropenic event. The result was not significant (RR
0.36; 95%CI 0.05 to 2.44) and had considerable heterogeneity (I2
= 97%; Analysis 2.1). Jones 1996 who applied GM-CSFs showed
a significant benefit for patients in the intervention group (RR
0.78; 95% CI 0.62 to 0.97).
Duration
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A pooled analysis of the duration of N4 could not be carried out
because trial authors did not report the required details (e.g. stan-
dard deviations). However, all studies that investigated the dura-
tion of N4 reported that, on average, N4 lasted two days longer in
the control groups compared to the CSF groups (Chevallier 1995;
Del Giglio 2008; Hansen 1995; Jones 1996; Romieu 2007 Table
7).
Infections
In three studies, 55 of 107 patients in the intervention groups
and 62 of 103 patients in the control groups experienced at least
one infectious complication (Chevallier 1995; Muhonen 1996;
Romieu 2007; Table 8). The RR was 0.86 (95% CI 0.72 to 1.02)
without heterogeneity among the trials (I2 = 0%; Analysis 2.4).
Hospitalization
In four studies, a total of six of 574 patients in the intervention
groups and 50 of 575 patients in the control groups were admitted
to hospital on at least one occasion (Hansen 1995; Jones 1996;
Romieu 2007; Vogel 2005; Table 9). The risk for hospitalization
was significantly reduced in CSF-treated patients (RR 0.14; 95%
CI 0.06 to 0.30) without heterogeneity among the trials (I2 = 0%;
NNTB 13; ARR 0.08; Analysis 2.5).
Subgroup analyses
First-cycle data and cumulated data across all chemotherapy
cycles
We only used data from Hansen 1995 who reported rates of pa-
tients hospitalized across all cycles of chemotherapy. None of the
11 patients in the intervention groups and one of nine patients
in the control groups were admitted to hospital on at least one
occasion, which was not significant (RR 0.28; 95% CI 0.01 to
6.10; Analysis 2.6). In three studies that reported the rates of pa-
tients hospitalized during cycle one, six of 563 patients in the in-
tervention groups and 49 of 566 patients in the control groups
were admitted to hospital. The meta-analysis showed significant
benefits for CSF-treated patients (RR 0.13; 95% CI 0.06 to 0.30)
and the results were homogeneous (I2 = 0%; Jones 1996; Romieu
2007 Vogel 2005).
G-CSF and GM-CSF
In the two studies applying G-CSF, five of the 493 patients in
the intervention groups and 45 of 494 patients in the control
groups were hospitalized (mainly for FN, severe neutropenia or
infections). The risk for being hospitalized was significantly lower
in the CSF groups (RR 0.12; 95% CI 0.05 to 0.29) and the
results were homogeneous (I2 = 0%; Romieu 2007; Vogel 2005;
Analysis 2.5). In the two studies applying GM-CSF, one out of 81
patients in the intervention groups and five of 81 patients in the
control groups were admitted to hospitals. The difference was not
significant (RR 0.26; 95% CI 0.04 to 1.56; Hansen 1995; Jones
1996) and there was no heterogeneity (I2 = 0%).
Use of intravenous antibiotics
In four studies, 22 of 781 patients in the intervention groups and
65 of 787 patients in the control groups were treated at least once
with i.v. antibiotics (Hansen 1995; Jones 1996; Papaldo 2003;
Vogel 2005; Table 9). The risk for being treatedwith i.v. antibiotics
was significantly lower in CSF-treated patients (RR 0.35; 95% CI
0.22 to 0.55) with low heterogeneity among the trials (I2 = 19%;
NNTB 18; ARR 0.05; Analysis 2.8).
Subgroup analyses
First-cycle data and cumulated data across all chemotherapy
cycles
In two studies, 16 of 248 patients in the intervention groups and
33 of 250 patients received i.v. antibiotics during all cycles of
chemotherapy (Hansen 1995; Papaldo 2003). The pooled risk for
antibiotic treatment was also significantly reduced (RR 0.50; 95%
CI 0.28 to 0.87) without heterogeneity (I2 = 0%; Analysis 2.9).
In two studies, six of 533 patients in the intervention groups and
32 of 537 patients in the control groups received i.v. antibiotics
in the first cycle of chemotherapy (Jones 1996; Vogel 2005). The
pooled risk for being treated was lower in the CSF group albeit
not significant (RR 0.40; 95% CI 0.03 to 4.77) with considerable
heterogeneity between the trials (I2 = 96%; Analysis 2.10).
The pooled risk for being treated with i.v. antibiotics was signif-
icantly lower in the two studies applying G-CSF (RR 0.35; 95%
CI 0.22 to 0.57; Papaldo 2003; Vogel 2005) with substantial het-
erogeneity between the two trials (I2 = 72%). In the two studies
applying GM-CSF, there was no significant difference in the risks
(RR 0.26; 95% CI 0.04 to 1.56) with no heterogeneity (I2 = 0%;
Hansen 1995; Jones 1996).
Administration of chemotherapy
In four studies, 674 out of 794 patients in the intervention
groups and 647 out of 794 patients in the control groups received
the planned chemotherapy cycles at scheduled times and doses
(Chevallier 1995; Papaldo 2003; Romieu 2007 Vogel 2005; Table
10). The RR was 1.05 (95% CI 0.97 to 1.13) with substantial
heterogeneity (I2 = 61%; Analysis 2.11). There were no GM-CSF
studies in the analysis.
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Adverse events
Bone pain
Two studies with a total of 151 patients reported the number
of patients with bone pain in both study arms (Chevallier 1995;
Muhonen 1996). Papaldo 2003 did not report the number of
patients with bone pain in the control group and therefore could
not be considered for analysis. The pooled risk (RR) for bone pain
was 5.88 for CSF-treated patients (95% CI 2.54 to 13.60) with
no heterogeneity (I2 = 0%; NNTH 3; Table 11 Analysis 2.12).
Injection-site reaction
Two studies with a total of 262 patients reported the number
of patients with injection-site reactions (Chevallier 1995; Jones
1996). The pooled risk (RR) for injection-site reactionwas 3.59 for
CSF-treated patients (95%CI 2.33 to 5.53) with no heterogeneity
(I2 = 0%, NNTH 3; Table 11 Analysis 2.13).
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D I S C U S S I O N
Summary of main results
This is the first systematic review and meta-analysis that has ad-
dressed the evidence for the use of CSFs on the prevention of FN
and its complications in patients with breast cancer undergoing
chemotherapy. We identified eight RCTs with a total of 2156 pa-
tients. The patients were treated with neoadjuvant (one study),
adjuvant (three studies) or palliative chemotherapy regimens (four
studies). Six studies used G-CSF (three filgrastim, two pegfilgras-
tim, one lenograstim) and two studies used GM-CSF (one mol-
gramostim and one sargramostim). The majority of studies were
judged as being at least at moderate risk of bias.
In our meta-analysis, CSFs significantly reduced the number of
patients with FN (RR 0.27; NNTB 12), early mortality (RR 0.32;
NNTB 79), the need for hospital care (RR 0.14; NNTB 13) and
the application of i.v. antibiotics (RR 0.35; NNTB 18). The du-
ration of FN or severe neutropenic events could not be assessed
because of the limited number of studies reporting this outcome
or the poor quality of reporting. CSFs frequently caused specific
short-term adverse effects like bone pain (RR 5.88; NNTH3) and
injection-site reactions (RR 3.59; NNTH 3) and did not signifi-
cantly reduce the risk of severe neutropenia, infections and infec-
tion-related mortality. The administration of CSFs did not confer
better maintenance of chemotherapy regimens at scheduled times
and doses.
Overall completeness and applicability of
evidence
This review summarized the evidence regarding primary prophy-
laxis of neutropenia-related complications with CSFs in a variety
of settings. The included trials comprised different breast cancer
samples (i.e. metastatic disease, adjuvant treatment situations, in-
flammatory cancers), investigated six different types of CSFs and
took place in different countries with different health care systems,
thus increasing the generalizability of these results. However, the
overall completeness of the review findings is limited and the ap-
plicability of evidence restricted owing to the following aspects.
First, more than 40% of the patients included in our analyses came
fromone studywith amoderate risk of bias and the overall number
of included studies was small.
Second, most outcomes were investigated insufficiently. For ex-
ample, fewer than half of the studies applied standard definitions
of FN and only one study differentiated the etiology of infections
or febrile episodes according to the definitions of the Interna-
tional Immunocompromised Host Society (ICHS). Furthermore,
most studies measured body temperature orally in order to detect
FN. There is not only clear evidence that the accuracy and reli-
ability of the measurement of body temperature depends on the
site and method of measurement but also that oral mucositis can
lead to inaccurate estimates when fever is measured orally. Ciu-
raru et al (Ciuraru 2008) found evidence that chemotherapy-as-
sociated mucositis in breast cancer patients increased the oral but
not systemic body temperature. They concluded that “mucositis
may provide an ’inflammation bias’ that could lead to the overuse
of antibiotics and growth factors in 20% to 40% of patients with
cancer” (Ciuraru 2008). In addition, although there was evidence
that the exact timing of blood counts during chemotherapy might
optimize G-CSF prophylaxis (Ammann 2002), only three trials
reported daily measurement schedules of body temperature and
ANCs. Hence, evidence of treatment effects on these outcomes or
on depending outcomes (e.g. hospitalization) needs to be inter-
preted carefully including the non-significant effects on the pre-
vention of severe neutropenia. Moreover, most trials were under-
powered to detect effects of CSF treatments on outcomes, which
rarely occur during treatment with chemotherapies with low to
moderate risk of FN such as infection-related and early mortality.
Third, five of the eight studies reported no deaths and in the re-
maining three studies, a very small number of events occurred.
Nineteen of 23 events were reported in one study and were at-
tributed to disease progression by the authors (Vogel 2005). The
reduction of all-cause mortality therefore might be attributed to
different risk factors rather than to treatment effects of CSFs.
Fourth, the trials’ study populations differed considerably regard-
ing baseline risks of FN and infections. Sensitivity analyses were
considered to examine the differential effects of CSFs on different
risk populations; however, the analyses were not feasible in the
present review, owing to the small number of trials per disease
stage or treatment situation. No studies were identified in which
the effectiveness of CSFs in breast cancer patients with different
risks were compared. Thus, conclusions cannot be drawn regard-
ing differential treatment effects depending on different risks.
Fifth, current guidelines on the use of CSFs during cancer che-
motherapy recommend prophylactic CSFs in chemotherapy reg-
imens with a risk of FN of more than 20%. However, only two
out of six studies that reported on this outcome had an incidence
of FN of more than 20% in the control group (Chevallier 1995;
Del Giglio 2008). All other studies had risks in the control groups
between 10% and 20% (Jones 1996; Romieu 2007; Vogel 2005)
or even below 10% (Papaldo 2003). Therefore, the results of our
analyses were based on trials in which CSFs were given to patients
of whom many, according to current guidelines, did not qualify
for prophylactic administration of CSFs.
Sixth, the application schedules of filgrastim examined in the in-
cluded trials varied considerably. Del Giglio 2008 scheduled fil-
grastim treatment 24 hours after chemotherapy, Muhonen 1996
on day four and Papaldo 2003 on day eight. The timing of fil-
grastim administration post-chemotherapy has profound effects
on hematologic recovery. There is evidence that the effectiveness
of filgrastim depends on its dose schedule (Crawford 1997) and
that beginning on day four to six yielded better hematologic re-
coveries compared with administration of filgrastim on day eight.
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The results of Papaldo 2003 furthermore suggested that not only
the beginning of CSF treatment but also a less intense schedule
with only two applications of filgrastim (day eight and 12 after
chemotherapy) could be as effective as the usually applied constant
dosing schedules. Hendler 2011 found possible benefit even for
shorter treatment schedules with filgrastim in patients with breast
cancer. Therefore, included trials with delayed and longer sched-
ules might have led to an underestimation of the treatment effect.
Seventh, several of the chemotherapy regimens in the included
studies were either uncommon drug combinations or rarely used
in the given schedule for the respective treatment situations
(Chevallier 1995; Del Giglio 2008; Hansen 1995; Muhonen
1996; Papaldo 2003).
Finally, current guidelines no longer recommend supportive treat-
ment withGM-CSFs (e.g. Aapro 2011; Crawford 2010), although
there is evidence that sargramostim could be a cost-effective alter-
native to filgrastim or pegfilgrastim in the prevention of FN and
related complications (Heaney 2009).
Quality of the evidence
The eight included RCTs differed with regards to their risk of bias
and quality of reporting. Only two trials were judged as having
only minor deficiencies in methodological quality. The results of
all other studies were deemed to be influenced by a certain de-
gree of selection, performance or detection bias owing to uncon-
cealed treatment allocation, lack of blinding of patients and care
providers, or unblinded outcome assessments. In addition, the
supportive treatments applied for the outcomes of interest (infec-
tions, etc.) were not adequately reported and might have individ-
ual variations, which would mask or bias the results.
Three trials declared possible conflicts of interest and five trials ac-
knowledged assistance from the pharmaceutical industry and sup-
ply of studymedication. In the largest trial, six out of the eight trial
authors were affiliated with themanufacturer of the interventional
drug. It has been shown that studies sponsored by pharmaceutical
companies were more likely to have outcomes favoring the spon-
sor than were studies with other sponsors (Higgins 2011).
Despite our comprehensive search strategy, there might be un-
published trials with non-significant results. We were not able to
obtain published protocols for most included trials in this review
and thus were not able to judge the risk of selective reporting for
these studies reliably.
Potential biases in the review process
This review considered the currently available information on this
topic. A comprehensive search of the literature was carried out
without any language restrictions and included Chinese databases.
It is of note that searches of the gray literature identified a large
Italian study that was planned as a four-arm study with two arms
investigating a research question related to CSF efficacy and was
probably eligible for inclusion in our review. However, those two
arms had not been carried out, according to the trial author, and
the other two arms had been published in 2005 (Venturini 2005).
It is also of note that one large ongoing study awaits assessment
(Amgen 2015) and may be included in an update of this review.
We contacted all relevant pharmaceutical companies but did not
receive any RCT data from them. There is the potential for publi-
cation bias, whichmight be an issue in this review given the virtual
non-existence of negative ndings that have been published, as
demonstrated in the funnel plot of the primary outcome FN.
When pooled analyses were performed for some outcomes, high
levels of heterogeneity were found. Heterogeneity appeared to re-
sult from differences in outcome definitions and the type of CSF
used.We carried out a subgroup analysis for the primary outcome,
FN, according to the cycle of chemotherapy in which the FN was
recorded (first cycle, all cycles) and the type of CSF (G-CSF, GM-
CSF), which suggested a higher preventive effectiveness of CSFs
during the first cycle and an advantage for G-CSF. Nevertheless,
these analyses included only six trials. Furthermore, we could not
perform any further subgroup analyses owing to the lack of data.
A meta-analysis of secondary outcomes, such as the duration of
neutropenia and hospitalization, could not be carried out since
these variables were not given as mean numbers or the trial authors
did not report standard deviations.
The findings of all outcomes should be regarded as uncertain be-
cause only results from up to six studies were available for the
analyses and the results on early mortality and infection-related
mortality were mainly based on the Vogel 2005 study, which was
judged to have a moderate risk of bias and contributed more than
40% of all patients to the meta-analyses.
Agreements and disagreements with other
studies or reviews
There are no published systematic reviews on the effectiveness of
CSFs on FN and its complications in patients with breast cancer
receiving chemotherapy. Two reviews in the area prior to this re-
view included two of our eight included trials in aggregated anal-
yses with other solid tumors (Kuderer 2007; Sung 2007). Kuderer
2007 was an update of Lyman 2002 with more included studies
and was republished in 2011 (Kuderer 2011).
Our findings were that the administration of CSFs helped to pre-
vent events of FN and reduced the need for hospital care, which
was in line with the findings from both reviews (Kuderer 2007;
Sung 2007). Kuderer 2007 furthermore found a reduction for all-
cause mortality during chemotherapy and infection-related mor-
tality across a broad range of different cancers, chemotherapy reg-
imens and baseline risks. We also detected a reduction of early
mortality; however, 19 of the 23 fatal events had occurred in only
one study and five out of eight studies in this analysis did not re-
port deaths during the study period. In accordance with the find-
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ings of Sung 2007 in their subgroup of solid tumors (in which
also lymphoma were included), we could not find a reduction in
infections or infection-related mortality.
In their analyses of trials with patients with solid tumors, Kuderer
2007 found a higher relative dose intensity of chemotherapy in
groups with CSFs. We also found a slightly higher rate of patients
in the CSF groups who had received the planned chemotherapy
cycles at scheduled times and doses.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In patients with breast cancer receiving chemotherapy, CSFs have
shown evidence of bene t in the prevention of FN. There is ev-
idence, though less reliable, of a decrease of all-cause mortality
during chemotherapy and a reduced need for hospital care. No
reliable evidence was found for a reduction of infection-related
mortality, a higher dose intensity of chemotherapy with CSFs or
diminished rates of severe neutropenia and infections. The ma-
jority of adverse events reported from CSF use were bone pain
and injection-site reactions but no conclusions could be drawn re-
garding late-term side effects. Most studies included in this review
used chemotherapy regimens with FN risks below the threshold
of 20% for which the administration of CSF is recommended by
current best practice guidelines. Nomeaningful conclusions could
be drawn concerning differential effects between the applied CSF
in these clinical settings owing to the small number of trials.
Implications for research
The evidence of benefit found in this review notwithstanding,
most of the studies included were of uncertain methodological
quality and some of them old and carried out before best practice
guidelines were implemented. However, observational data sug-
gest that, based on current guidelines, CSFs are underutilized for
chemotherapy regimens with high risk of FN and overutilized for
those with low risk (Ramsey 2010). In addition, there are doubts
that the current management of FN in patients with breast cancer
is cost-effective, even if it follows current best practice guidelines
(Trueman 2009). Furthermore, there is evidence that not only
CSFs but also antibiotics are successful in reducing infectious com-
plications in cancer patients receiving chemotherapy (Gafter-Gvili
2009; Herbst 2009).
Thus, arguments could be made for clinical trials comparing the
efficiency of different supportive treatment strategies in prevent-
ing FN and its associated morbidity and mortality after chemo-
therapy with low and moderate FN risk for breast cancer. Future
studies should adhere to adequate concealment of randomization
and blinding of the interventions and assessment of outcomes (or
both), should report data on all-cause mortality, and provide con-
cise definitions as well as properly timedmeasurements of the out-
comes under study.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chevallier 1995
Methods Design: 2-arm, double-blind, placebo-controlled, Phase III trial
Follow up: after the induction period, patients were evaluated every 4 months for the
first 2 years, biannually for the next 3 years, and once per year thereafter
Ethical approval: yes
Participants No. of patients randomized: 120
No. of patients evaluated: 101 (for tumor response)
Stage of cancer: invasive and inflammatory breast cancer (T4d)
Demographics: women, age range 23 to 65 years (mean age: 48 years)
Setting: multicenter study; France
Informed consent: yes (written)
Interventions CSF intervention: G-CSF: lenograstim, 5 µg/kg/d; d6-15 sc;
Control: identical placebo
Basic treatment: FEC-HD: 5-fluorouracil 750 mg/m2 d1-4, epirubicin 35 mg/m2 d2-
4, cyclophosphamide 400 mg/m2 d2-4); every 21d; 4 cycles;
Supportive treatment: antibiotics (i.v. or oral, or both) for treatment of FN (primary
or secondary prophylaxis was unclear); antibiotics were given in different schedules and
dosages according to 3 predefined categories of infections
Outcomes Primary outcome measures: duration of neutropenia
Secondary outcome measures: incidence of FN; events of FN; ANC profiles; incidence
of infections; hospitalization and antibiotic treatment; dose delays; OS and DFS; tumor
response; toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation/allocation
concealment (selection bias)
Low risk Quote: ”[…] patients were randomized
[…]“
Comment: sequence generation was n.r.
Allocation concealment was n.r. Patient
characteristics at baselinewere similarly dis-
tributed. Sample size > 100 patients
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: ”[...] a double-blind administration
of lenograstim versus vehicle was chosen.“
Comment: n.s.* whether placebowas iden-
tically looking but owing to use of vehicle,
adequate process of blinding was assumed;
possible risk of unblinding owing to CSF-
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Chevallier 1995 (Continued)
specific adverse drug reactions
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding of outcome assess-
ment n.r.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “[...] 16 withdrew from the study
(13 placebo and three lenograstim) for the
following reasons [...]”
Comment: attrition rate 13%; reasons for
withdrawal were n.r. separately for each
group; attrition rate was not equally dis-
tributed between groups
Selective reporting (reporting bias) Low risk Comment: no indication for selective re-
porting
Definitions and measurements of out-
comes
Low risk Comment: FN clearly defined; body tem-
perature was measured twice daily, blood
cell counts daily
Supportive treatment Unclear risk Comment: systemic antibiotic treatment in
case of FN; precisely described clinical pro-
cedural method; patients in CGs were as-
sumed to have received antibiotics more
frequent
Del Giglio 2008
Methods Design: 3-arm, open-label Phase III trial
Follow-up: 10 months
Ethical approval: yes
Participants No. of patients randomized: 348
No. of patients evaluated: 348
Stage of cancer: high-risk breast cancer stage II-IV
Demographics: women, age range 25 to 74 years
Setting: multicenter study; Belarus, Slovenia, South Africa, Brazil, Chile, Russia, Hun-
gary, Lithuania, Romania, Poland
Informed consent: yes (written)
Interventions CSF intervention: G-CSF: filgrastim (XM02 or Neupogen), 5 µg/kg/d; d2 until ANC
≥ 10 × 109/L after nadir (minimum until d6, maximum until d15) sc
Control: identical placebo
Basic treatment: doxorubicin 60 mg/m2, DCT 75 mg/m2; d1 i.v.; every 21d; maximum
4 cycles
Supportive treatment: no information about administration of antibiotics
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Del Giglio 2008 (Continued)
Outcomes Primary outcome measures: duration of neutropenia in cycle 1
Secondary outcome measures: incidence of FN; ANC profile
Notes Drug approval study for a filgrastim biosimilar (XM02)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation/allocation
concealment (selection bias)
Unclear risk Quote: “[...] patients were randomized in a
2:2:1 ratio [...]”
Comment: sequence generation was n.r.;
allocation concealment was n.r. Slight dif-
ferences in the distribution of prior radia-
tion therapy between treatment arms: IG1
(XM02): 10.7%, IG2(Neupogen): 6.6%;
CG: 12.5%. Sample size > 100 patients
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “A true double-blind design was
not feasible because XM02 and Neupogen
were formulated in different volumes. [...
]”
Comment: unblinded study personnel;
blinding of patients was unclear; no details
about the placebo were reported
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “investigator was kept blinded and
performed all assessments [...]”
Comment: probably done
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Nine patients (2.6%) discontin-
ued the study due to an AE [adverse event],
i.e., 2(1.4%) patients in the XM02 group
[...]”
Comment: attrition rate 2.6%; reasons for
withdrawal were n.r. separately for each
group
Selective reporting (reporting bias) Low risk Antibiotic treatment was n.r.
Definitions and measurements of out-
comes
Unclear risk 2 different definitions of FN; it was not
stated which was applied
Daily measurement of body temperature
and blood cell counts
Supportive treatment Unclear risk Quote: “Secondary endpoints included [...
] and of protocol defined FN (administra-
tion of systemic antibiotics) [...]”
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Del Giglio 2008 (Continued)
Comment: patients in CGs were assumed
tohave received antibioticsmore frequently
Hansen 1995
Methods Design: 2-arm, open-label, Phase III trial
Follow-up: unclear
Ethical approval: yes
Participants No. of patients randomized: 20
No. of patients evaluated: 18 (for tumor response)
Stage of cancer: metastatic breast cancer, stage IV
Demographics: women, age range 37-61 years (median age: CSF IG: 56 years; CG: 50
years)
Setting: single-center study; Denmark
Informed consent: yes (n.s.)
Interventions CSF intervention: GM-CSF: molgramostim, 5 µg/kg/d; d2-11 sc
Control: no treatment
Basic treatment: HD-cyclophosphamide 2.5 g/m2; d1 i.v.; or HD-epirubicin 130 mg/
m2; d1 i.v.; every 21d; 4 cycles
Supportive treatment: antibiotics (i.v.) for treatment of FN (if applied as primary or
secondary prophylaxis was unclear)
Outcomes Primary outcome measures: neutropenia duration
Secondary outcome measures: FN duration; ANC profiles; antibiotic usage owing to
FN; hospitalization; FN events; tumor response
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation/allocation
concealment (selection bias)
High risk Quote: “[...] patients were randomly as-
signed to [...]”
Comment: sequence generation was n.r.
Allocation concealment was n.r. Differ-
ences existed in pretreatment and in sites
of metastases. Sample size < 100 patients
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: no statements about blinding
or any use of placebo, thus we judged the
study as an open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: unblinded outcome assessment
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Hansen 1995 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “In the treatment arm two patient’s
did not receive all [...] courses [...] In the
control arm, one patient ceased treatment
[...]”
Comment: attrition rate 15%; reasons
stated for each group
Selective reporting (reporting bias) Unclear risk Reporting the incidence of events instead
and no rates of patients with neutropenia
Definitions and measurements of out-
comes
Unclear risk FN not defined; daily measuring of body
temperature and blood cell counts
Supportive treatment Unclear risk Comment: incidence and duration of an-
tibiotic treatmentwas a secondary outcome
measure, criteria of administration was not
stated
Jones 1996
Methods Design: 2 arm, double-blind, placebo-controlled, Phase III trial
Follow-up: 5 years poststudy to monitor disease status and survival
Ethical approval: yes
Participants No. of patients randomized: 142
No. of patients evaluated: 131
Stage of cancer: T1N1 - T2N1- others (stage II-III)
Demographics: women, age range 25 to 69 years (mean age 47 years)
Setting: single-center study; USA
Informed consent: yes
Interventions CSF intervention: GM-CSF: sargramostim, 250 µg/m2; d3-15 sc
Control: identical placebo
Basic treatment: FAC-MD: fluorouracil 600 mg/m2, cyclophosphamide 750 mg/m2,
antimycin 60 mg/m2; d1 i.v.; every 21d; 4 cycles
Supportive treatment: prophylactic antibiotics (i.v., oral, or both) at the onset of grade
III neutropenia (ANC < 1000/µL)
Outcomes Primary outcome measures: neutropenia duration
Secondary outcome measures: neutropenia incidence; FN incidence; dose intensity; hos-
pitalization; antibiotic use owing to FN; toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
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Jones 1996 (Continued)
Random sequence generation/allocation
concealment (selection bias)
Low risk Quote: “[...] patients were randomized to
[...]”
Comment: sequence generation was n.
r. Allocation concealment was n.r. There
were no significant differences in sociode-
mographic and disease related parameters.
Sample size > 100 patients
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “Patients [...] received the study
drug [...] in a double blind manner”; “[...]
equivalent volume of placebo [...]”
Comment: method of blinding adequate;
unblinding owing to specific adverse drug
reactions could not be ruled out
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding of outcome assess-
ment n.r.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “there were three early withdrawals
among patients randomized to placebo and
eight among patients randomized to GM-
CSF”
Comment: attrition rate 8%; reasons stated
for each study group; attrition rate was not
equally distributed between groups
Selective reporting (reporting bias) Low risk Comment: no indication for selective re-
porting
Definitions and measurements of out-
comes
Low risk FN clearly defined; body temperature was
measured daily and blood cell counts 3
times weekly
Supportive treatment Unclear risk Quote: “[…] at the onset of grade 3 neu-
tropenia (ANC<1000/µl) patients received
prophylactic antibiotics”
Comment: patients in CGs were assumed
tohave received antibioticsmore frequently
Muhonen 1996
Methods Design: 2-arm, open label, Phase III trial
Follow-up: unclear
Ethical approval: unclear
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Muhonen 1996 (Continued)
Participants No. of patients randomized: 32
No. of patients evaluated: 31
Stage of cancer: metastatic or loco-regionally advanced breast cancer
Demographics: women, age range 34 to 65 years (median age: IG: 51 years; CG: 52
years)
Setting: multicenter study; Finland
Informed consent: yes (verbal)
Interventions CSF intervention: G-CSF: filgrastim, 5 µg/kg; d4-17 sc
Control: no treatment
Basic treatment: MMM-StD: mitomycin 8 mg/m2 d1, mitoxantrone 8 mg/m2 d1 and
22, methotrexate 35 mg/m2 d1 and 22; i.v.; every 42d; 6 cycles
Supportive treatment: no information about the administration of antibiotics
Outcomes Primary outcome measure: neutropenia incidence
Secondary outcome measures: infections; toxicity; dose delays; tumor response; survival
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation/allocation
concealment (selection bias)
Unclear risk Quote: “Patients [...] were randomly as-
signed to [...]”
Comment: sequence generation was n.r.
Allocation concealment was n.r. Slight dif-
ferences in hormone pretreatment. Sample
size < 100 patients
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: no statements about blinding
or any use of placebo, thus we judged the
study as an open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: unblinded outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “one patient did not fulfil the en-
try criteria [...] and was removed from the
study [...]”
Comment: attrition rate 1%; no drop-outs
during study period
Selective reporting (reporting bias) High risk Comment: no information on rates or
events of FN provided
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Muhonen 1996 (Continued)
Definitions and measurements of out-
comes
High risk FN not defined; no statements about body
temperature measurements and blood cell
counts
Supportive treatment Unclear risk Comment: no information about adminis-
tration of antibiotics
Papaldo 2003
Methods Design: 4-arm, open-label, Phase III trial
Follow-up: median 55 months
Ethical approval: yes
Participants No. of patients randomized: 506
No. of patients evaluated: 497
Stage of cancer: stage I or II breast cancer
Demographics: women, age range 25 to 65 years (median age: IG1: 47 years; IG2: 48
years; CG1: 47 years; CG2: 47 years)
Setting: multicenter study; Italy
Informed consent: yes
Interventions CSF intervention: G-CSF: filgrastim, 5 different schedules: 480 µg/d, d8 - 14; 480 µg/
d, d8,10,12,14; 300 µg/, d8 - 14; 300 µg/d, d8,10,12,14; 300 µg/d, d8, 12;
Control: no treatment
Basic treatment: epirubicin 120 mg/m2, cyclophosphamide 600 mg/m2; d1 i.v.; every
21d; 4 cycles
Supportive treatment: antibiotics (i.v.) for treatment of a documented infection
Outcomes Primary outcome measures: DFS and OS
Secondary outcome measures: FN incidence; neutropenia incidence; toxicity
Notes -
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation/allocation
concealment (selection bias)
Unclear risk Quote: “[...] were randomly assigned to [.
..] patients and tumor characteristics were
well balanced among the groups”
Comment: sequence generation was n.r.
Allocation concealment was n.r. Slight dif-
ferences in numbers of patients with in-
volved lymph nodes, tumor size and recep-
tor status between study arms. Sample size
> 100 patients
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Papaldo 2003 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Comment: no statements about blinding
or any use of placebo; thus we judged the
study as an open-label study
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: unblinded outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Low risk Quote: “Nine patients were not assessable
for DFS and OS because [...]”
Comment: attrition rate 2%; reasons for
withdrawal were n.r. separately for each
group
Selective reporting (reporting bias) Unclear risk Number of documented infections n.r.
Definitions and measurements of out-
comes
High risk FN clearly defined; no information about
measurements of body temperature, blood
cell counts once weekly
Supportive treatment Unclear risk Quote: “[...] antibiotics given for a docu-
mented infection”
Romieu 2007
Methods Design: 2 arm, open-label, Phase II trial
Follow-up: 16 months
Ethical approval: yes
Participants No. of patients randomized: 60
No. of patients evaluated: 59
Stage of cancer: node-positive breast cancer stage II-III
Demographics: women, age range 65 to 77 years
Setting: multicenter study; Germany, Spain, Italy, France
Informed consent: yes (written)
Interventions CSF intervention: G-CSF: pegfilgrastim, 6 mg/d; d2 sc
Control: no treatment in cycle 1
Basic treatment: FEC-100: 5-fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclo-
phosphamide 500 mg/m2; d1 i.v.; every 21d; 4 to 6 cycles
Supportive treatment: secondary prophylaxis with antibiotics in case of FN
Outcomes Primary outcome measure: neutropenic events in cycle 1
Secondary outcome measures: neutropenic events (all cycles); dose intensity; ANC pro-
files
Notes -
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Romieu 2007 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation/allocation
concealment (selection bias)
Unclear risk Quote: “[...] based on an open-label pre-
determined randomization schedule gener-
ated by a statistician [...] treatment groups
were randomly assigned (1:1) using an in-
teractive voice response system”
Comment: owing to the reported proce-
dure, we assumed an adequate sequence
generation and concealed allocation. Sam-
ple size < 100 patients
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “this open-label, phase 2 study [...
]”
Comment: unblinded patients and person-
nel
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Comment: unblinded outcome assessment
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “three patients in the PP [primary
prophylaxis] group and four from the SP
[secondary prophylaxis] group were with-
drawn [...]”
Comment: attrition rate 12%; reasons
stated for each study group
Selective reporting (reporting bias) Unclear risk Comment: no outcome on hematologic
data (ANC, etc.) provided; antibiotic treat-
ment was n.r
Definitions and measurements of out-
comes
Low risk FNclearly defined; dailymeasuring of body
temperature; blood cell counts were taken
3 times weekly
Supportive treatment Unclear risk Quote: “secondary prophylaxis (antibiotic)
was allowed inpatientswhodevelopedFN”
Comment: patients in CGs seemed to have
received antibiotics more frequently
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Vogel 2005
Methods Design: 2-arm, double blind, placebo-controlled, Phase III trial
Follow-up: not stated
Ethical approval: yes
Participants No. of patients randomized: 928
No. of patients evaluated: 928
Stage of cancer: metastatic and non-metastatic breast cancer
Demographics: women (922), men (6), age range 21 to 88 years (mean 52 years)
Setting: multicenter study; 88 sites in Europe and the USA
Informed consent: yes
Interventions CSF intervention: G-CSF: pegfilgrastim, 6 mg; d2 sc;
Control: identical placebo
Basic treatment: DCT-HD: DCT 100 mg/m2; d1 i.v.; every 21d; 4 cycles
Supportive treatment: antibiotics (i.v.) secondary prophylaxis for FN treatment; non-
narcotic analgesics and opioids for bone pain
Outcomes Primary outcome measure: FN incidence
Secondary outcome measures: neutropenia incidence; hospitalization; antibiotic usage
owing to FN; dose delays; toxicity
Notes Large multinational drug approval study
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation/allocation
concealment (selection bias)
Unclear risk Quote: “Patients were randomly assigned
to [...] the groups were well matched in
characteristics [...]”
Comment: sequence generation was n.r.;
allocation concealment was n.r. Slight dif-
ferences in percentages of previous radia-
tion therapy and chemotherapy and in first
quartile of ANC. Sample size >100patients
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Quote: “[...] all patients received at least
one dose of blinded study drug [...] and
placebowere presented as identical prefilled
syringes”
Comment: identical placebo; unblinding
owing to specific adverse drug reactions
could not be ruled out
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Comment: blinding of outcome assess-
ment n.r.
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Vogel 2005 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Quote: “thirty-five patients (8%) in the ini-
tial placebo group and 27 (6%) in the peg-
filgrastim group withdrew from the study”
Comment: attrition rate 7%; reasons stated
for each study group
Selective reporting (reporting bias) Unclear risk Comment: number of dropped-out pa-
tients in cycle 1 not stated
Definitions and measurements of out-
comes
Unclear risk FN not clearly defined; body temperature
was measured twice daily, blood cell counts
once weekly in case of fever
Supportive treatment Unclear risk Quote: “[...] the incidence of need for IV
anti-infectives as a result of FN.”
Comment: patients in CGs were assumed
tohave received antibioticsmore frequently
ANC: absolute neutrophil count; CG: control group; CSF: colony-stimulating factors; d: day; DCT: docetaxel; DFS: disease-free sur-
vival; FAC: fluorouracil, antimycin, cyclophosphamide; FEC: fluorouracil, epirubicin, cyclophosphamide; FEC-HD: fluorouracil,
epirubicin, cyclophosphamide high-dose; FN: febrile neutropenia; G-CSF: granulocyte colony-stimulating factors; GM-CSF: gran-
ulocyte-macrophage colony-stimulating factors; HD: high-dose; IG: intervention group; ITT: intention-to-treat; i.v.: intravenous;
MMM: mitomycin, mitoxantrone, methotrexate; No.: number; n.r.: not reported; n.s.: not significant; OS: overall survival; sc:
subcutaneous.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Ardizzoni 1994 Different chemotherapy schedules between study arms
Athanassiou 1996 Different chemotherapy schedules between study arms
Bono 2009 Different basic treatments between study arms; no placebo or no-treatment control
Ellis 2011 Different basic treatments between study arms
Gascon 2010 No placebo or no-treatment control
Gebbia 1994 No data available for breast cancer patients; author was contacted several times but did not answer
Green 2003 No placebo or no-treatment control
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Hatam 2011 Different basic treatments between study arms and no application of CSFs
Holmes 2002 No placebo or no-treatment control
Holmes 2002b No placebo or no-treatment control
Iiristo 2011 Different basic treatments between study arms
Ikonomidis 2008 Study reported only biochemical parameters and no outcomes of interest of our systematic review. Study
author was contacted for additional data but did not answer
Joensuu 2010 Different basic treatments between study arms
Khrichkova 2008 No information about randomization and recruitment of patients. Study did not report on outcomes of
interest for our systematic review
Martin 2006 Different basic treatments between study arms
Schröder 1999 No placebo or no-treatment control
Steger 1992 Not clear how many patients were included in the trial. The publication reports only data for injection-site
reaction experienced by patients receiving GM-CSF. Author was contacted but could not provide data
Stöger 1998 Different chemotherapy schedules between study arms
Tomova 2009 Different basic treatments between study arms
Venturini 2005 Patients in the G-CSF arm received chemotherapy every 2 weeks, while patients in the control arms received
chemotherapy every 3 weeks
von Minckwitz 2008a Treatment with CSFs was not randomly allocated
von Minckwitz 2010 Different basic treatments between study arms
von Minckwitz 2011 Different basic treatments between study arms and no control arm with placebo or no treatment
Waller 2010 No placebo or no-treatment control
Wang 2004 Unclear cross-over design; no placebo or no-treatment control
Weaver 2001 No placebo or no-treatment control
Yau 1996 Outcomes of interests of our review only reported aggregated with data from patients with lymphoma.
Author was contacted but did not answer
Zhang 1999 Cross-over study; no placebo or no-treatment control
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Zhou 2006 No placebo or no-treatment control
CSF: colony-stimulating factors; G-CSF: granulocyte colony-stimulating factors; GM-CSF: granulocyte-macrophage colony-stimulat-
ing factors.
Characteristics of ongoing studies [ordered by study ID]
Amgen 2015
Trial name or title A Prospective Observational Study of Neutropenia and Anemia Management in Subjects With Solid Tumors
Receiving Myelotoxic Chemotherapy
Methods Prospective observational study
Participants Breast cancer, non-small cell lung cancer, ovarian cancer and small cell lung cancer patients; the aim is to have
approximately 800 breast cancer, 300 non-small cell lung cancer, 100 small-cell lung cancer and 100 ovarian
cancer subjects
Interventions Chemotherapy and primary, secondary or no usage of G-CSF
Outcomes Primary outcome measure: incidence of febrile neutropenia; secondary outcome measure: G-CSF use, ESA
use, anti-infective use, transfusions and hospitalizations
Starting date December 2007
Contact information Amgen Call Center
Notes -
ESA: erythropoiesis-stimulating agents; G-CSF: granulocyte colony-stimulating factor.
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D A T A A N D A N A L Y S E S
Comparison 1. Primary outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Febrile neutropenia rates (total) 6 2073 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.11, 0.70]
1.1 G-CSF 5 1931 Risk Ratio (M-H, Random, 95% CI) 0.27 [0.10, 0.75]
1.2 GM-CSF 1 142 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.03, 2.24]
2 Febrile neutropenia rates (all
cycles)
2 598 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.09, 2.24]
2.1 G-CSF 2 598 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.09, 2.24]
3 Febrile neutropenia rates (first
cycles)
4 1475 Risk Ratio (M-H, Random, 95% CI) 0.20 [0.08, 0.52]
3.1 G-CSF 3 1333 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.06, 0.61]
3.2 GM-CSF 1 142 Risk Ratio (M-H, Random, 95% CI) 0.26 [0.03, 2.24]
4 Early mortality 8 2143 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.13, 0.77]
4.1 G-CSF 6 1981 Risk Ratio (M-H, Fixed, 95% CI) 0.32 [0.13, 0.77]
4.2 GM-CSF 2 162 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Infection-related mortality 8 2143 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.29]
5.1 G-CSF 6 1981 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.29]
5.2 GM-CSF 2 162 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Comparison 2. Secondary Outcomes
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Neutropenia grade IV (total) 4 712 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.17, 1.18]
1.1 G-CSF 3 570 Risk Ratio (M-H, Random, 95% CI) 0.36 [0.05, 2.44]
1.2 GM-CSF 1 142 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.62, 0.97]
2 Neutropenia grade IV (all cycle) 2 511 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.08, 0.45]
2.1 G-CSF 2 511 Risk Ratio (M-H, Random, 95% CI) 0.19 [0.08, 0.45]
2.2 GM-CSF 0 0 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Neutropenia grade IV (first
cycle)
2 201 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.66, 1.21]
3.1 G-CSF 1 59 Risk Ratio (M-H, Random, 95% CI) 1.06 [0.79, 1.43]
3.2 GM-CSF 1 142 Risk Ratio (M-H, Random, 95% CI) 0.78 [0.62, 0.97]
4 Infections (total) 3 210 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.72, 1.02]
4.1 G-CSF 3 210 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.72, 1.02]
5 Hospitalization (total) 4 1149 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.06, 0.30]
5.1 G-CSF 2 987 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.05, 0.29]
5.2 GM-CSF 2 162 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.04, 1.56]
6 Hospitalization (all cycles) 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.01, 6.10]
6.1 GM-CSF 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.01, 6.10]
7 Hospitalization (first cycle) 3 1129 Risk Ratio (M-H, Fixed, 95% CI) 0.13 [0.06, 0.30]
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7.1 G-CSF 2 987 Risk Ratio (M-H, Fixed, 95% CI) 0.12 [0.05, 0.29]
7.2 GM-CSF 1 142 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.03, 2.24]
8 Antibiotics (total) 4 1568 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.22, 0.55]
8.1 G-CSF 2 1406 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.22, 0.57]
8.2 GM-CSF 2 162 Risk Ratio (M-H, Fixed, 95% CI) 0.26 [0.04, 1.56]
9 Antibiotics (all cycles) 2 498 Risk Ratio (M-H, Fixed, 95% CI) 0.50 [0.28, 0.87]
9.1 G-CSF 1 478 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.29, 0.90]
9.2 GM-CSF 1 20 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.01, 6.10]
10 Antibiotics (first cycle) 2 1070 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.03, 4.77]
10.1 G-CSF 1 928 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.07, 0.46]
10.2 GM-CSF 1 142 Risk Ratio (M-H, Random, 95% CI) 0.85 [0.76, 0.95]
11 Chemotherapy, planned dose
in time
4 1588 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.97, 1.13]
11.1 G-CSF 4 1588 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.97, 1.13]
12 Bone pain 2 151 Risk Ratio (M-H, Fixed, 95% CI) 5.88 [2.54, 13.60]
12.1 G-CSF 2 151 Risk Ratio (M-H, Fixed, 95% CI) 5.88 [2.54, 13.60]
13 Injection-site reaction 2 262 Risk Ratio (M-H, Fixed, 95% CI) 3.59 [2.33, 5.53]
13.1 G-CSF 1 120 Risk Ratio (M-H, Fixed, 95% CI) 3.39 [1.85, 6.20]
13.2 GM-CSF 1 142 Risk Ratio (M-H, Fixed, 95% CI) 3.81 [2.05, 7.05]
Analysis 1.1. Comparison 1 Primary outcomes, Outcome 1 Febrile neutropenia rates (total).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 1 Primary outcomes
Outcome: 1 Febrile neutropenia rates (total)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G-CSF
Romieu 2007 0/30 3/29 7.2 % 0.14 [ 0.01, 2.56 ]
Papaldo 2003 3/237 16/241 17.0 % 0.19 [ 0.06, 0.65 ]
Vogel 2005 5/463 51/465 19.4 % 0.10 [ 0.04, 0.24 ]
Del Giglio 2008 34/276 25/70 22.6 % 0.34 [ 0.22, 0.54 ]
Chevallier 1995 36/61 42/59 23.4 % 0.83 [ 0.64, 1.08 ]
Subtotal (95% CI) 1067 864 89.5 % 0.27 [ 0.10, 0.75 ]
Total events: 78 (CSF), 137 (Control)
Heterogeneity: Tau?? = 1.00; Chi?? = 44.17, df = 4 (P<0.00001); I?? =91%
Test for overall effect: Z = 2.53 (P = 0.012)
2 GM-CSF
Jones 1996 1/70 4/72 10.5 % 0.26 [ 0.03, 2.24 ]
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(. . . Continued)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Subtotal (95% CI) 70 72 10.5 % 0.26 [ 0.03, 2.24 ]
Total events: 1 (CSF), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 1137 936 100.0 % 0.27 [ 0.11, 0.70 ]
Total events: 79 (CSF), 141 (Control)
Heterogeneity: Tau?? = 0.96; Chi?? = 44.82, df = 5 (P<0.00001); I?? =89%
Test for overall effect: Z = 2.72 (P = 0.0065)
Test for subgroup differences: Chi?? = 0.00, df = 1 (P = 0.96), I?? =0.0%
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Analysis 1.2. Comparison 1 Primary outcomes, Outcome 2 Febrile neutropenia rates (all cycles).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 1 Primary outcomes
Outcome: 2 Febrile neutropenia rates (all cycles)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G-CSF
Papaldo 2003 3/237 16/241 43.4 % 0.19 [ 0.06, 0.65 ]
Chevallier 1995 36/61 42/59 56.6 % 0.83 [ 0.64, 1.08 ]
Total (95% CI) 298 300 100.0 % 0.44 [ 0.09, 2.24 ]
Total events: 39 (CSF), 58 (Control)
Heterogeneity: Tau?? = 1.21; Chi?? = 6.94, df = 1 (P = 0.01); I?? =86%
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
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Analysis 1.3. Comparison 1 Primary outcomes, Outcome 3 Febrile neutropenia rates (first cycles).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 1 Primary outcomes
Outcome: 3 Febrile neutropenia rates (first cycles)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G-CSF
Romieu 2007 0/30 3/29 8.8 % 0.14 [ 0.01, 2.56 ]
Vogel 2005 5/463 51/465 33.6 % 0.10 [ 0.04, 0.24 ]
Del Giglio 2008 34/276 25/70 43.6 % 0.34 [ 0.22, 0.54 ]
Subtotal (95% CI) 769 564 86.0 % 0.19 [ 0.06, 0.61 ]
Total events: 39 (CSF), 79 (Control)
Heterogeneity: Tau?? = 0.71; Chi?? = 7.88, df = 2 (P = 0.02); I?? =75%
Test for overall effect: Z = 2.76 (P = 0.0057)
2 GM-CSF
Jones 1996 1/70 4/72 14.0 % 0.26 [ 0.03, 2.24 ]
Subtotal (95% CI) 70 72 14.0 % 0.26 [ 0.03, 2.24 ]
Total events: 1 (CSF), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 839 636 100.0 % 0.20 [ 0.08, 0.52 ]
Total events: 40 (CSF), 83 (Control)
Heterogeneity: Tau?? = 0.50; Chi?? = 7.78, df = 3 (P = 0.05); I?? =61%
Test for overall effect: Z = 3.28 (P = 0.0010)
Test for subgroup differences: Chi?? = 0.06, df = 1 (P = 0.80), I?? =0.0%
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Analysis 1.4. Comparison 1 Primary outcomes, Outcome 4 Early mortality.
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 1 Primary outcomes
Outcome: 4 Early mortality
Study or subgroup CSF Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G-CSF
Chevallier 1995 0/61 0/59 0.0 [ 0.0, 0.0 ]
Papaldo 2003 0/254 0/243 0.0 [ 0.0, 0.0 ]
Muhonen 1996 0/16 0/15 0.0 [ 0.0, 0.0 ]
Romieu 2007 0/30 1/29 0.32 [ 0.01, 7.61 ]
Del Giglio 2008 1/276 2/70 0.13 [ 0.01, 1.38 ]
Vogel 2005 5/463 14/465 0.36 [ 0.13, 0.99 ]
Subtotal (95% CI) 1100 881 0.32 [ 0.13, 0.77 ]
Total events: 6 (CSF), 17 (Control)
Heterogeneity: Chi?? = 0.62, df = 2 (P = 0.73); I?? =0.0%
Test for overall effect: Z = 2.55 (P = 0.011)
2 GM-CSF
Jones 1996 0/70 0/72 0.0 [ 0.0, 0.0 ]
Hansen 1995 0/11 0/9 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 81 81 0.0 [ 0.0, 0.0 ]
Total events: 0 (CSF), 0 (Control)
Heterogeneity: Chi?? = 0.0, df = 0 (P<0.00001); I?? =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 1181 962 0.32 [ 0.13, 0.77 ]
Total events: 6 (CSF), 17 (Control)
Heterogeneity: Chi?? = 0.62, df = 2 (P = 0.73); I?? =0.0%
Test for overall effect: Z = 2.55 (P = 0.011)
Test for subgroup differences: Not applicable
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Analysis 1.5. Comparison 1 Primary outcomes, Outcome 5 Infection-related mortality.
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 1 Primary outcomes
Outcome: 5 Infection-related mortality
Study or subgroup CSF Control Risk Ratio Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G-CSF
Chevallier 1995 0/61 0/59 0.0 [ 0.0, 0.0 ]
Muhonen 1996 0/16 0/15 0.0 [ 0.0, 0.0 ]
Papaldo 2003 0/254 0/243 0.0 [ 0.0, 0.0 ]
Romieu 2007 0/30 0/29 0.0 [ 0.0, 0.0 ]
Del Giglio 2008 0/276 1/70 0.09 [ 0.00, 2.08 ]
Vogel 2005 0/463 2/465 0.20 [ 0.01, 4.17 ]
Subtotal (95% CI) 1100 881 0.14 [ 0.02, 1.29 ]
Total events: 0 (CSF), 3 (Control)
Heterogeneity: Chi?? = 0.15, df = 1 (P = 0.70); I?? =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
2 GM-CSF
Hansen 1995 0/11 0/9 0.0 [ 0.0, 0.0 ]
Jones 1996 0/70 0/72 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 81 81 0.0 [ 0.0, 0.0 ]
Total events: 0 (CSF), 0 (Control)
Heterogeneity: Chi?? = 0.0, df = 0 (P<0.00001); I?? =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 1181 962 0.14 [ 0.02, 1.29 ]
Total events: 0 (CSF), 3 (Control)
Heterogeneity: Chi?? = 0.15, df = 1 (P = 0.70); I?? =0.0%
Test for overall effect: Z = 1.73 (P = 0.083)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours CSF Favours control
50Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer
patients (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 2.1. Comparison 2 Secondary Outcomes, Outcome 1 Neutropenia grade IV (total).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 1 Neutropenia grade IV (total)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G-CSF
Muhonen 1996 4/16 12/15 22.1 % 0.31 [ 0.13, 0.76 ]
Papaldo 2003 13/237 101/243 24.9 % 0.13 [ 0.08, 0.23 ]
Romieu 2007 23/30 21/29 26.3 % 1.06 [ 0.79, 1.43 ]
Subtotal (95% CI) 283 287 73.4 % 0.36 [ 0.05, 2.44 ]
Total events: 40 (CSF), 134 (Control)
Heterogeneity: Tau?? = 2.80; Chi?? = 77.79, df = 2 (P<0.00001); I?? =97%
Test for overall effect: Z = 1.05 (P = 0.29)
2 GM-CSF
Jones 1996 43/70 57/72 26.6 % 0.78 [ 0.62, 0.97 ]
Subtotal (95% CI) 70 72 26.6 % 0.78 [ 0.62, 0.97 ]
Total events: 43 (CSF), 57 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Total (95% CI) 353 359 100.0 % 0.44 [ 0.17, 1.18 ]
Total events: 83 (CSF), 191 (Control)
Heterogeneity: Tau?? = 0.93; Chi?? = 77.99, df = 3 (P<0.00001); I?? =96%
Test for overall effect: Z = 1.62 (P = 0.10)
Test for subgroup differences: Chi?? = 0.62, df = 1 (P = 0.43), I?? =0.0%
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Analysis 2.2. Comparison 2 Secondary Outcomes, Outcome 2 Neutropenia grade IV (all cycle).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 2 Neutropenia grade IV (all cycle)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G-CSF
Muhonen 1996 4/16 12/15 42.1 % 0.31 [ 0.13, 0.76 ]
Papaldo 2003 13/237 101/243 57.9 % 0.13 [ 0.08, 0.23 ]
Subtotal (95% CI) 253 258 100.0 % 0.19 [ 0.08, 0.45 ]
Total events: 17 (CSF), 113 (Control)
Heterogeneity: Tau?? = 0.25; Chi?? = 2.80, df = 1 (P = 0.09); I?? =64%
Test for overall effect: Z = 3.79 (P = 0.00015)
2 GM-CSF
Subtotal (95% CI) 0 0 0.0 % 0.0 [ 0.0, 0.0 ]
Total events: 0 (CSF), 0 (Control)
Heterogeneity: not applicable
Test for overall effect: not applicable
Total (95% CI) 253 258 100.0 % 0.19 [ 0.08, 0.45 ]
Total events: 17 (CSF), 113 (Control)
Heterogeneity: Tau?? = 0.25; Chi?? = 2.80, df = 1 (P = 0.09); I?? =64%
Test for overall effect: Z = 3.79 (P = 0.00015)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 Secondary Outcomes, Outcome 3 Neutropenia grade IV (first cycle).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 3 Neutropenia grade IV (first cycle)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G-CSF
Romieu 2007 23/30 21/29 44.5 % 1.06 [ 0.79, 1.43 ]
Subtotal (95% CI) 30 29 44.5 % 1.06 [ 0.79, 1.43 ]
Total events: 23 (CSF), 21 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
2 GM-CSF
Jones 1996 43/70 57/72 55.5 % 0.78 [ 0.62, 0.97 ]
Subtotal (95% CI) 70 72 55.5 % 0.78 [ 0.62, 0.97 ]
Total events: 43 (CSF), 57 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Total (95% CI) 100 101 100.0 % 0.89 [ 0.66, 1.21 ]
Total events: 66 (CSF), 78 (Control)
Heterogeneity: Tau?? = 0.03; Chi?? = 2.71, df = 1 (P = 0.10); I?? =63%
Test for overall effect: Z = 0.74 (P = 0.46)
Test for subgroup differences: Chi?? = 2.69, df = 1 (P = 0.10), I?? =63%
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Analysis 2.4. Comparison 2 Secondary Outcomes, Outcome 4 Infections (total).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 4 Infections (total)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G-CSF
Romieu 2007 2/30 2/29 3.2 % 0.97 [ 0.15, 6.41 ]
Muhonen 1996 6/16 7/15 11.4 % 0.80 [ 0.35, 1.85 ]
Chevallier 1995 47/61 53/59 85.3 % 0.86 [ 0.73, 1.01 ]
Total (95% CI) 107 103 100.0 % 0.86 [ 0.72, 1.02 ]
Total events: 55 (CSF), 62 (Control)
Heterogeneity: Chi?? = 0.04, df = 2 (P = 0.98); I?? =0.0%
Test for overall effect: Z = 1.72 (P = 0.085)
Test for subgroup differences: Not applicable
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Analysis 2.5. Comparison 2 Secondary Outcomes, Outcome 5 Hospitalization (total).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 5 Hospitalization (total)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G-CSF
Romieu 2007 0/30 3/29 7.0 % 0.14 [ 0.01, 2.56 ]
Vogel 2005 5/463 42/465 82.1 % 0.12 [ 0.05, 0.30 ]
Subtotal (95% CI) 493 494 89.1 % 0.12 [ 0.05, 0.29 ]
Total events: 5 (CSF), 45 (Control)
Heterogeneity: Chi?? = 0.01, df = 1 (P = 0.93); I?? =0.0%
Test for overall effect: Z = 4.72 (P < 0.00001)
2 GM-CSF
Hansen 1995 0/11 1/9 3.2 % 0.28 [ 0.01, 6.10 ]
Jones 1996 1/70 4/72 7.7 % 0.26 [ 0.03, 2.24 ]
Subtotal (95% CI) 81 81 10.9 % 0.26 [ 0.04, 1.56 ]
Total events: 1 (CSF), 5 (Control)
Heterogeneity: Chi?? = 0.00, df = 1 (P = 0.97); I?? =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 574 575 100.0 % 0.14 [ 0.06, 0.30 ]
Total events: 6 (CSF), 50 (Control)
Heterogeneity: Chi?? = 0.61, df = 3 (P = 0.89); I?? =0.0%
Test for overall effect: Z = 4.99 (P < 0.00001)
Test for subgroup differences: Chi?? = 0.59, df = 1 (P = 0.44), I?? =0.0%
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Analysis 2.6. Comparison 2 Secondary Outcomes, Outcome 6 Hospitalization (all cycles).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 6 Hospitalization (all cycles)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 GM-CSF
Hansen 1995 0/11 1/9 100.0 % 0.28 [ 0.01, 6.10 ]
Total (95% CI) 11 9 100.0 % 0.28 [ 0.01, 6.10 ]
Total events: 0 (CSF), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 2.7. Comparison 2 Secondary Outcomes, Outcome 7 Hospitalization (first cycle).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 7 Hospitalization (first cycle)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G-CSF
Romieu 2007 0/30 3/29 7.2 % 0.14 [ 0.01, 2.56 ]
Vogel 2005 5/463 42/465 84.8 % 0.12 [ 0.05, 0.30 ]
Subtotal (95% CI) 493 494 92.0 % 0.12 [ 0.05, 0.29 ]
Total events: 5 (CSF), 45 (Control)
Heterogeneity: Chi?? = 0.01, df = 1 (P = 0.93); I?? =0.0%
Test for overall effect: Z = 4.72 (P < 0.00001)
2 GM-CSF
Jones 1996 1/70 4/72 8.0 % 0.26 [ 0.03, 2.24 ]
Subtotal (95% CI) 70 72 8.0 % 0.26 [ 0.03, 2.24 ]
Total events: 1 (CSF), 4 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 1.23 (P = 0.22)
Total (95% CI) 563 566 100.0 % 0.13 [ 0.06, 0.30 ]
Total events: 6 (CSF), 49 (Control)
Heterogeneity: Chi?? = 0.41, df = 2 (P = 0.81); I?? =0.0%
Test for overall effect: Z = 4.91 (P < 0.00001)
Test for subgroup differences: Chi?? = 0.40, df = 1 (P = 0.53), I?? =0.0%
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Analysis 2.8. Comparison 2 Secondary Outcomes, Outcome 8 Antibiotics (total).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 8 Antibiotics (total)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G-CSF
Vogel 2005 5/463 28/465 42.8 % 0.18 [ 0.07, 0.46 ]
Papaldo 2003 16/237 32/241 48.6 % 0.51 [ 0.29, 0.90 ]
Subtotal (95% CI) 700 706 91.4 % 0.35 [ 0.22, 0.57 ]
Total events: 21 (CSF), 60 (Control)
Heterogeneity: Chi?? = 3.53, df = 1 (P = 0.06); I?? =72%
Test for overall effect: Z = 4.22 (P = 0.000024)
2 GM-CSF
Hansen 1995 0/11 1/9 2.5 % 0.28 [ 0.01, 6.10 ]
Jones 1996 1/70 4/72 6.0 % 0.26 [ 0.03, 2.24 ]
Subtotal (95% CI) 81 81 8.6 % 0.26 [ 0.04, 1.56 ]
Total events: 1 (CSF), 5 (Control)
Heterogeneity: Chi?? = 0.00, df = 1 (P = 0.97); I?? =0.0%
Test for overall effect: Z = 1.47 (P = 0.14)
Total (95% CI) 781 787 100.0 % 0.35 [ 0.22, 0.55 ]
Total events: 22 (CSF), 65 (Control)
Heterogeneity: Chi?? = 3.69, df = 3 (P = 0.30); I?? =19%
Test for overall effect: Z = 4.47 (P < 0.00001)
Test for subgroup differences: Chi?? = 0.10, df = 1 (P = 0.75), I?? =0.0%
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Analysis 2.9. Comparison 2 Secondary Outcomes, Outcome 9 Antibiotics (all cycles).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 9 Antibiotics (all cycles)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G-CSF
Papaldo 2003 16/237 32/241 95.1 % 0.51 [ 0.29, 0.90 ]
Subtotal (95% CI) 237 241 95.1 % 0.51 [ 0.29, 0.90 ]
Total events: 16 (CSF), 32 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.31 (P = 0.021)
2 GM-CSF
Hansen 1995 0/11 1/9 4.9 % 0.28 [ 0.01, 6.10 ]
Subtotal (95% CI) 11 9 4.9 % 0.28 [ 0.01, 6.10 ]
Total events: 0 (CSF), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Total (95% CI) 248 250 100.0 % 0.50 [ 0.28, 0.87 ]
Total events: 16 (CSF), 33 (Control)
Heterogeneity: Chi?? = 0.14, df = 1 (P = 0.71); I?? =0.0%
Test for overall effect: Z = 2.44 (P = 0.015)
Test for subgroup differences: Chi?? = 0.14, df = 1 (P = 0.71), I?? =0.0%
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Analysis 2.10. Comparison 2 Secondary Outcomes, Outcome 10 Antibiotics (first cycle).
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 10 Antibiotics (first cycle)
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G-CSF
Vogel 2005 5/463 28/465 48.2 % 0.18 [ 0.07, 0.46 ]
Subtotal (95% CI) 463 465 48.2 % 0.18 [ 0.07, 0.46 ]
Total events: 5 (CSF), 28 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.57 (P = 0.00035)
2 GM-CSF
Jones 1996 58/70 70/72 51.8 % 0.85 [ 0.76, 0.95 ]
Subtotal (95% CI) 70 72 51.8 % 0.85 [ 0.76, 0.95 ]
Total events: 58 (CSF), 70 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 2.76 (P = 0.0058)
Total (95% CI) 533 537 100.0 % 0.40 [ 0.03, 4.77 ]
Total events: 63 (CSF), 98 (Control)
Heterogeneity: Tau?? = 3.07; Chi?? = 27.19, df = 1 (P<0.00001); I?? =96%
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Chi?? = 10.35, df = 1 (P = 0.00), I?? =90%
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Analysis 2.11. Comparison 2 Secondary Outcomes, Outcome 11 Chemotherapy, planned dose in time.
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 11 Chemotherapy, planned dose in time
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 G-CSF
Romieu 2007 17/30 7/29 1.1 % 2.35 [ 1.15, 4.81 ]
Chevallier 1995 49/58 34/46 11.4 % 1.14 [ 0.93, 1.40 ]
Vogel 2005 370/463 363/465 38.4 % 1.02 [ 0.96, 1.09 ]
Papaldo 2003 238/243 243/254 49.0 % 1.02 [ 0.99, 1.06 ]
Total (95% CI) 794 794 100.0 % 1.05 [ 0.97, 1.13 ]
Total events: 674 (CSF), 647 (Control)
Heterogeneity: Tau?? = 0.00; Chi?? = 7.65, df = 3 (P = 0.05); I?? =61%
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 2.12. Comparison 2 Secondary Outcomes, Outcome 12 Bone pain.
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 12 Bone pain
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G-CSF
Muhonen 1996 3/16 0/15 9.2 % 6.59 [ 0.37, 117.77 ]
Chevallier 1995 30/61 5/59 90.8 % 5.80 [ 2.42, 13.94 ]
Total (95% CI) 77 74 100.0 % 5.88 [ 2.54, 13.60 ]
Total events: 33 (CSF), 5 (Control)
Heterogeneity: Chi?? = 0.01, df = 1 (P = 0.93); I?? =0.0%
Test for overall effect: Z = 4.13 (P = 0.000036)
Test for subgroup differences: Not applicable
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Analysis 2.13. Comparison 2 Secondary Outcomes, Outcome 13 Injection-site reaction.
Review: Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients
Comparison: 2 Secondary Outcomes
Outcome: 13 Injection-site reaction
Study or subgroup CSF Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 G-CSF
Chevallier 1995 35/61 10/59 50.8 % 3.39 [ 1.85, 6.20 ]
Subtotal (95% CI) 61 59 50.8 % 3.39 [ 1.85, 6.20 ]
Total events: 35 (CSF), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 3.95 (P = 0.000078)
2 GM-CSF
Jones 1996 37/70 10/72 49.2 % 3.81 [ 2.05, 7.05 ]
Subtotal (95% CI) 70 72 49.2 % 3.81 [ 2.05, 7.05 ]
Total events: 37 (CSF), 10 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 4.25 (P = 0.000021)
Total (95% CI) 131 131 100.0 % 3.59 [ 2.33, 5.53 ]
Total events: 72 (CSF), 20 (Control)
Heterogeneity: Chi?? = 0.07, df = 1 (P = 0.79); I?? =0.0%
Test for overall effect: Z = 5.81 (P < 0.00001)
Test for subgroup differences: Chi?? = 0.07, df = 1 (P = 0.79), I?? =0.0%
0.001 0.01 0.1 1 10 100 1000
Favours CSF Favours control
A D D I T I O N A L T A B L E S
Table 1. Characteristics of studies - chemotherapy regimen
Study Chemotherapy
Chevallier 1995 Agents (FEC-HD): 5-fluorouracil: 750 mg/m2, d1-4; epirubicin: 35 mg/m2 d2-4; cyclophosphamide: 400 mg/
m2, d2-4
Schedule: every 3 weeks
Cycles: 4
Jones 1996 Agents (FAC): 5-fluorouracil: 600 mg/m2, d1; doxorubicin 60 mg/m2 d1; cyclophosphamide: 750 mg/m2, d1
Schedule: every 3 weeks
Cycles: 4
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Table 1. Characteristics of studies - chemotherapy regimen (Continued)
Del Giglio 2008 Agents: (TA) doxorubicin: 60 mg/m2, d1, docetaxel: 75 mg/m2, d1
Schedule: every 3 weeks
Cycles: 4
Romieu 2006 Agents (FEC): 5-fluorouracil: 500 mg/m2, d1; epirubicin: 100 mg/m2, d1; cyclophosphamide: 500 mg/m2, d1
Schedule: every 3 weeks
Cycles: 4-6 cycles
Papaldo 2003 Agents (EC): epirubicin: 120 mg/m2, d1; cyclophosphamide: 600 mg/m2, d1
Schedule: every 3 weeks
Cycles: 4
Hansen 1995 Agents (HD-E/HD-C): cyclophosphamide: 2.5 g/m2, d1 or epirubicin: 130 mg/m2, d1
Schedule: every 3 weeks
Cycles: 4
Vogel 2005 Agents (D): docetaxel: 100 mg/m2, d1
Schedule: every 3 weeks
Cycles: 4
Muhonen 1996 Agents (MMM): mitomycin: 8 mg/m2, d1; mitoxantrone: 8 mg/m2, d1 and 22; methotrexate: 35 mg/m2 d1 and
22
Schedule: every 6 weeks
Cycles: 6
d: day.
Table 2. Characteristics of studies - type of applied CSF
Study CSF Type Dosage and administration
Chevallier 1995 G-CSF Lenograstim (filgrastim) rHuG-CSF 5 µg/kg/d (d6-15)
Del Giglio 2008 XM02/Neupogen (filgrastim) r-metHuG-CSF 5 µg/kg/d (d2-6/15)
Muhonen 1996 Filgrastim 5 µg/kg/d
(d4-17/d24-37)
Papaldo 2003 Filgrastim cohort 1: 480 µg/d (d8-14)
cohort 2: 480 µg/d (d8, 10, 12, 14)
cohort 3: 300 µg/d (d8-14)
cohort 4: 300 µg/d (d8, 10, 12, 14)
cohort 5: 300 µg/d (d8, 12)
Vogel 2005 Neulasta (pegfilgrastim) rHuG-CSF 6 mg (d2)
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Table 2. Characteristics of studies - type of applied CSF (Continued)
Romieu 2006 Pegfilgrastim 6 mg (d2)
Hansen 1995 GM-CSF Molgramostim 5 µg/kg/d (d2-11)
Jones 1996 Sargramostim 250 µg/m2 (d3-15)
CSF: colony-stimulating factors; d: day of administration; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-
macrophage colony-stimulating factor; rHuG-CSF: recombinant human colony-stimulating factor
Table 3. Results - definition and measurement of febrile neutropenia
Study Definition Measurement
Fever
(°C)
Neutropenia (WHO grade) Fever
• time point
• time period
• measured by
• documented in
Neutropenia
Chevallier 1995 ≥ 38.2 III and IV • twice daily
• duringCX and after discharge
• recorded by a nurse
• diary
daily (1st cycle)
3 times/week (2nd to 4th cycle)
Jones 1996 ≥ 38.2 IV • each morning
• while on study
• patients (ucl)
• diary
thrice/week
Del Giglio 2008 2 different definitions, unclear which was ap-
plied
• daily
• from d1 until at least d15
• n.r.
• n.r.
from d2 until at least d15
Romieu 2006 > 38.0 IV • daily
• during CX until d30 after
study
• n.r.
• n.r.
3 times/week until ANC ≥ 2.0
× 109/L then weekly
Papaldo 2003 ≥ 38.2 IV • n.r.
• n.r.
• n.r.
• n.r.
weekly
Hansen 1995 n.r. n.r. • daily
• between each cycle
daily
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Table 3. Results - definition and measurement of febrile neutropenia (Continued)
• n.r.
• n.r.
Vogel 2005 ≥ 38.2 IV (on the same day of fever or
day after)
• twice daily
• n.r.
• patient
• n.r.
weekly if febrile
Muhonen 1996 n.r. n.r. • n.r.
• n.r.
• n.r.
• n.r.
n.r.
ANC: absolute neutrophil count; CX: chemotherapy; d: day of administration; n.r.: not reported.
Table 4. Results - rates of neutropenia/febrile neutropenia
Study CSF Neutropenia
grade IV
Neutropenia
grade III-IV
Febrile neutropenia
Intervention Control Intervention Control Intervention Control
Chevallier
1995
G-CSF - - - - 36/61
(59%)
E/Cy:
47/240
(19.6%)
42/59
(71.2%) ns
E/Cy:
67/214
(31.3%)
Del Giglio
2008
(1st cycle)
- - - - 34/276
12.3%
25/70
(36.1%)*
Muhonen
1996
4/16
(25%)
12/15
(80%)*
- - - -
Papaldo 2003 13/237
(5.4%)
101/243
(41.6%)
68/237
(28.6%)
198/243
(81.6%)*
3/237
(1.2%)
16/241
(6.6%)*
Vogel 2005 - - - - 6/463
(1%)
1st cycle:
5/463
< 1%
78/465
(17%) *
1st cycle:
51/465
11%
Romieu 2006
(1st cycle)
23/30
(77%)
21/29
(72%)
- - 1/30
(3.3%)
5/29
(17.2%)‡
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Table 4. Results - rates of neutropenia/febrile neutropenia (Continued)
Hansen 1995 GM-CSF E/Cy:
24/39
(62%)
E/Cy:
29/31
(94%)
- - E/Cy:
8/39
(21%)
E/Cy:
10/31
(32%)
Jones 1996
(1st cycle)
43/70
(61%)
57/72
(79%)
- - 6/70
(9%)
1st cycle:
1/70
(1%)
8/72
(11%)
1st cycle:
4/72
(6%)
* = significant (P < 0.05).
‡ + stated as serious febrile neutropenia events.
CSF: colony-stimulating factor; E/Cy: events per cycle; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-
macrophage colony-stimulating factor; ns: not significant.
Table 5. Results - early mortality
Study CSF Reason Number of events
Intervention Control
Chevallier 1995 G-CSF - 0/61 0/59
Del Giglio 2008 IG: ischemic stroke; CG: sepsis,
cardiorespiratory arrest
1/276
(0.3%)
2/70
(2.9%)
Vogel 2005 IG: 5; CG: 12, all attributed to
disease progression; CG: 2, re-
lated to infectious events
5/463
(1%)
14/465*
(3%)
Romieu 2006 CG: cardiac failure 0/30 1/29
Hansen 1995 - 0/11 0/9
Papaldo 2003 - 0/254 0/243
Jones 1996 GM-CSF - 0/70 0/72
Muhonen 1996 - 0/16 0/15
* - significant (P < 0.05).
CG: control group; CSF: colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage
colony-stimulating factor; IG: intervention group.
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Table 6. Results - infection related mortality
Study CSF Reason Number of events
Intervention Control
Chevallier 1995 G-CSF - 0/61 0/59
Del Giglio 2008 during cycle 1: CG: 1 sepsis 0/276 1/70
(1.4%)
Vogel 2005 CG: 2 sepsis 0/463 2/465
(0.4%)
Romieu 2006 - 0/30 0/29
Hansen 1995 - 0/11 0/9
Papaldo 2003 - 0/254 0/243
Jones 1996 GM-CSF - 0/70 0/72
Muhonen 1996 - 0/16 0/15
CG: control group; CSF: colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage
colony-stimulating factor.
Table 7. Results - duration of severe neutropenia (grade IV)
Study CSF Duration of neutropenia grade IV (days)
Intervention Control
Chevallier 1995 G-CSF 2 6*
Romieu 2006 1st cycle:
1 (mn)
1st cycle:
3 (mn)
Del Giglio 2008 1st cycle:
1.1 (mn)
1st cycle:
3.9 (mn)
Hansen 1995 GM-CSF 4 (md) 8 (md)
Jones 1996 1st cycle:
2 (md)
1st cycle:
7* (md)
* = significant (P < 0.05).
CSF: colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating
factor; md: median; mn: mean.
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Table 8. Results - rates of patients with infections
Study CSF Intervention Control
Chevallier 1995 G-CSF 47/61
(77%)
53/59
(89.8%) ns
Muhonen 1996 6/16
(37.5%)
7/15
(46.7%) ns
Romieu 2006 (1st cycle) GM-CSF 2/30
(7%)
2/29
(7%) ns
CSF: colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating
factor; ns: not significant.
Table 9. Results - hospitalization and administration of antibiotics
Study CSF Hospitalization Administration of antibiotics
Intervention Control Decision Mode Intervention Control Decision
Papaldo
2003
G-CSF - - - i.v. 16/237
(7%)
32/241*
(13%)
Not stated
Vogel 2005 6/463
(1%)
1st cycle:
5/463
(1%)
64/465
(14%)*
1st cycle:
42/465
(9%) nsp
In case of a
clinical diag-
nosis of FN
i.v. 7/463
(2%)
1st cycle:
1%
48/465
(10%)*
1st cycle:
6%
In case of FN
Romieu
2006
0/30
(0%)
3/29
(10,3%)
In case of FN
(N4and>38
°C)
i.v. - - -
Hansen
1995
GM-CSF 0/11
(0%)
1/9
(11%) nsp
Not stated i.v. 0/11
(0%)
1/9
(11%) nsp
Not stated
Jones 1996 6/70
(9%)
1st cycle:
1/70
(1%)
8/72
(11%)
1st cycle:
4/72 nsp
(6%)
In case of FN Ciprofloxa-
cin orally
twice daily
(500 mg)
i.v.
1st cycle:
58/70
(83%)
1/70
(1%)
1st cycle:
70/72
(97%)
4/72
(6%)
At the on-
set of N3
until recov-
ery patients
received an-
tibiotics
(orally)
Hospital-
ized patients
received an-
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Table 9. Results - hospitalization and administration of antibiotics (Continued)
tibiotics (i.v.
)
* = significant (P < 0.05).
CSF: colony-stimulating factor; FN: febrile neutropenia; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-
macrophage colony-stimulating factor; i.v.: intravenous; N3: grade III neutropenia; N4: grade IV neutropenia; nsp: not specified.
Table 10. Results - administration of chemotherapies
Study CSF Rates of patients who received the planned chemotherapy cycles at scheduled times and doses
Intervention Control
Chevallier 1995 G-CSF Retreatment at the planned date for cycles 2, 3, 4
51/61 (84%)
51/60 (85%)
49/58 (84%)
46/57 (81%)
33/52 (63%)
34/46 (74%)
Papaldo 2003 Epirubicin dose intensity: 98.1% 95.5%
Vogel 2005 Patients who received planned dose on time: 80% 78%
Romieu 2006 RDI 100%: 17 (57%)
RDI 95% to 100%: 9 (30%)
RDI 90% to 95%: 2 (7%)
RDI < 90%: 2 (7%)
7 (24%)
12 (41%)
6 (21%)
4 (14%)
CSF: colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; RDI: relative dose intensity.
Table 11. Results - adverse events
Study CSF Bone pain Injection-site reactions
Intervention Control Intervention Control
Chevallier 1995 G-CSF 30/61
(49%)
5/59
(8%)
35/61
(57%)
10/59
(17%)
Muhonen 1996 3/16
(19%)
0/15
(0%)
- -
Papaldo 2003 101/237
(42.6%)
Not stated - -
Vogel 2005 146/463
(31%)
126/465
(27%)
- -
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Table 11. Results - adverse events (Continued)
Jones 1996 GM-CSF - - 37/70
(53%)
10/72
(14%)*
* = significant (P < 0.05).
CSF: colony-stimulating factor; G-CSF: granulocyte colony-stimulating factor; GM-CSF: granulocyte-macrophage colony-stimulating
factor.
A P P E N D I C E S
Appendix 1. DIMDI search strategy
(colony-stimulating factors OR
granulocyte colony-stimulating factor OR
granulocyte colony stimulating factor, recombinant OR
granulocyte-macrophage colony-stimulating factor OR
granulocyte macrophage colony-stimulating factors, recombinant OR
filgrastim OR
granulocyte colony-stimulating factor OR
recombinant granulocyte colony stimulating factor OR
g csf OR
gcsf OR
granulocyte-macrophage colony-stimulating factor OR
gm csf OR
recombinant granulocyte macrophage colony-stimulating factor OR
gmcsf OR
pegfilgrastim OR
lenograstim OR
sargramostim OR
filgrastim OR
neupogen OR
granocyte OR
neulasta OR
biograstim OR
ratiograstim OR
XM02 OR
Immunex OR
Leukine OR
Leucomax OR
Molgramostin OR
Granulokin OR
Granulokine OR
Nivestim OR
Tevagrastim OR
Zarzio OR
SCH 39300 OR
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Neupopeg OR
Regramostim OR
Prokine)
AND
(Control Group* OR
Placebos OR
Randomized Controlled Trial OR
Controlled Clinical Trial OR
Clinical Trial, Phase III OR
Clinical Trial, Phase IV OR
Placebos)
AND
(breast neoplasms OR
breast OR
carcinoma, ductal, breast OR
breast neoplasms OR
breast cancer OR
mamma OR
breast ductal carcinoma OR
mammary ductal carcinoma OR)
AND
(Antineoplastic protocols OR
Chemotherapy, adjuvant OR
Neoadjuvant therapy OR
Antineoplastic combined chemotherapy protocols OR
Chemotherapy)
limits: “Mensch” (human) AND “Krebserkrankungen” (cancer diseases)
Appendix 2. Clinicaltrials.gov and WHO ICTRP search strategy
WHO ICTRP “advanced search” strategy
in the title:
colony-stimulating factors OR
granulocyte colony-stimulating factor OR
granulocyte colony stimulating factor, recombinant OR
granulocyte-macrophage colony-stimulating factor OR
granulocyte macrophage colony-stimulating factors, recombinant OR
filgrastim OR
granulocyte colony-stimulating factor OR
recombinant granulocyte colony stimulating factor OR
g csf OR
gcsf OR
granulocyte-macrophage colony-stimulating factor OR
gm csf OR
recombinant granulocyte macrophage colony-stimulating factor OR
gmcsf OR
pegfilgrastim OR
lenograstim OR
sargramostim OR
filgrastim OR
neupogen OR
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granocyte OR
neulasta OR
biograstim OR
ratiograstim OR
XM02 OR
Immunex OR
Leukine OR
Leucomax OR
Molgramostin OR
Granulokin OR
Granulokine OR
Nivestim OR
Tevagrastim OR
Zarzio OR
SCH 39300 OR
Neupopeg OR
Regramostim OR
Prokine
in the condition:
breast neoplasms OR
breast OR
carcinoma, ductal, breast OR
breast neoplasms OR
breast cancer OR
mamma OR
breast ductal carcinoma OR
mammary ductal carcinoma
in the intervention: -
all recruitment status
all countries
every date of registration
Clinicaltrials.gov search strategy
(colony-stimulating factors OR
granulocyte colony-stimulating factor OR
granulocyte colony stimulating factor, recombinant OR
granulocyte-macrophage colony-stimulating factor OR
granulocyte macrophage colony-stimulating factors, recombinant OR
filgrastim OR
granulocyte colony-stimulating factor OR
recombinant granulocyte colony stimulating factor OR
g csf OR
gcsf OR
granulocyte-macrophage colony-stimulating factor OR
gm csf OR
recombinant granulocyte macrophage colony-stimulating factor OR
gmcsf OR
pegfilgrastim OR
lenograstim OR
sargramostim OR
filgrastim OR
neupogen OR
granocyte OR
neulasta OR
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biograstim OR
ratiograstim OR
XM02 OR
Immunex OR
Leukine OR
Leucomax OR
Molgramostin OR
Granulokin OR
Granulokine OR
Nivestim OR
Tevagrastim OR
Zarzio OR
SCH 39300 OR
Neupopeg OR
Regramostim OR
Prokine) [ALL-FIELDS]
AND “Interventional” [STUDY-TYPES]
AND
(breast neoplasms OR
breast OR
carcinoma AND ductal AND breast OR
breast neoplasms OR
breast cancer OR
mamma OR
breast ductal carcinoma OR
mammary ductal carcinoma) [DISEASE]
Appendix 3. Chinese Databases search strategy
VIP Database:
AND ti 0
AND kw 0
AND FN ti 0
AND FN kw 4
CSF AND ti 0
CSF AND kw 0
CSF AND FN ti 19
CSF AND FN kw 15
CNKI
AND ti 0
AND kw 1
AND mesh 10
AND FN ti 0
AND FN kw 0
AND FN mesh 14
CSF AND ti 1
CSF AND kw 0
CSF AND mesh 10
CSF AND FN ti 1
CSF AND FN kw 0
CSF AND FN mesh 61
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CBM Database
AND ti 0
AND ab 3
AND FN ti 0
AND FN ab 5
CSF AND ti 1
CSF AND ab 4
CSF AND FN ti 0
CSF AND FN ab 17
H I S T O R Y
Protocol first published: Issue 3, 2009
Review first published: Issue 10, 2012
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S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• AG Biologische Krebstherapie, Deutsche Krebshilfe (70-301), Germany.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
The published protocol included ’mortality related to infections’ as a primary outcome. We have since split up mortality to include:
early mortality (during the study) and infection-related mortality (during the study) for clarity in the review.
76Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer
patients (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
